netFormulary
 Report : A-Z of formulary items 05/06/2020 16:23:55
[Back]
 
Section Name Details
A5.03.01 Medihoney® Wound Gel 

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

14.04 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II
05.03.01 Abacavir Ziagen®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

05.03.01 Abacavir and Lamivudine Kivexa®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

05.03.01 Abacavir and Lamivudine and Zidovudine Trizivir®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

10.01.03 Abatacept Orencia®

Red Traffic Light For the treatment of

  • Rheumatoid arthritis as per NICE TA195 (APCO September 2010) and NICE TA375 (APCO May 2013). Also see Clinical Commissioning Policy 201D.
  • Juvenile idiopathic arthritis as per NICE TA373. Funded by specialised commissioning. (APCO January 2016).

Black Traffic Light Not recommended for treating psoriatic arthritis after DMARDs (terminated appraisal) as per NICE TA568 (APCO May 2018). 

02.09 Abciximab 

Secondary care use only. 

08.01.05 Abemaciclib Verzenios®
  • For previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as per NICE TA563 (APCO March 2019).
  • With fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579 (APCO July 2019). Funded by specialised commissioning. 
08.03.04.02 Abiraterone Zytiga®

For the treatment of:

  • Castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen as per NICE TA259 (APCO July 2012).
  • Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated as per NICE TA387 (APCO May 2016).


Funded by specialised commissioning.

04.10.01 Acamprosate Campral EC®

Suitable for continuation in primary care following specialist initiation.

06.01.02.03 Acarbose Glucobay®

APCO September 2016.

02.08.02 Acenocoumarol Sinthrome®

NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.

11.06 Acetazolamide 

Suitable for continuation in primary care following specialist initiation.

11.06 Acetazolamide Diamox® Secondary care use only.
12.01.01 Acetic Acid 2% Earcalm® Spray

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

Also available to purchase over the counter. 

18 Acetylcysteine 

Secondary care use only. 

05.03.02.01 Aciclovir 

Treatment for Herpes Zoster or Shingles, in line with In line with Guidelines for Antibiotic Prescribing in the Community 2018.

12.03.02 Aciclovir 

Cold sores resolve after 7–10d without treatment. Topical over the counter antivirals (aciclovir) can be purchased in line with Clinical Commissioning Policy 88D.

See Guidelines for Antibiotic Prescribing in the Community 2018.

13.10.03 Aciclovir Zovirax®

Cold sores resolve after 7–10d without treatment. Topical over the counter antivirals (aciclovir) can be purchased in line with Clinical Commissioning Policy 88D.

See Guidelines for Antibiotic Prescribing in the Community 2018.

13.05.02 Acitretin Neotigason®

For prescribing by dermatologists only in secondary care.

NB. Women of child-bearing potential should be on at least one, or preferably two, complementary forms of effective contraception (e.g. barrier and hormonal) for at least 1 month before starting treatment, during treatment, and for at least 3 years after stopping treatment.

APCO March 2007.

03.01.02 Aclidinium Eklira Genuair®

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

03.01.04 Aclidinium and Formoterol Duaklir Genuair®

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

03.04.01 Acrivastine Benadryl® Allergy Relief

Available to purchase over the counter.

Only prescribe if required on a continuous basis for chronic rhinosinusitis and chronic urticaria, in line with Clinical Commissioning Policy 88D

A5.08.07 Actico® 

For single use only and must be ordered on ONPOS, in line with  OCCG Wound Management Formulary.

APCO May 2015. 

For more information, please see Guidance for Selecting Alternatives to Foams. 

A5.08.03 Acti-Fast® 2-way stretch 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

NB. Elasticated viscose stockinette for securing dressings in place when adhesive dressing or tape is not clinically indicated. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

A5.02.01 ActiFormCool® 

This dressing donates and absorbs fluid. Needs to be cut to size of wound. 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

APCO May 2015.

 

A5.03.01 Actilite® 

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

13.08.01 Actinica lotion 

For prescribing by dermatologists only in secondary care. For daylight photodynamic therapy (PDT). 

APCO March 2018.

01.05.03 Adalimumab Humira®

For the treatment of:

 

10.01.03 Adalimumab Humira®

For the treatment of:

    • Ankylosing spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383 (APCO March 2016).
    • Juvenile idiopathic arthritis as per NICE TA373 (APCO January 2016). Funded by specialised commissioning.
    • Rheumatoid arthritis as per NICE TA195 (APCO September 2010) and NICE TA375 (APCO March 2016). Also see Clinical Commissioning Policy 201D.
    • Psoriatic arthritis as per NICE TA199 (APCO September 2010). For sequential use please refer to Clinical Commissioning Policy 268A.

 

11.99.99.99 Adalimumab 

For the treatment of:

    • Severe refractory uveitis as per NHSE policy 170010/PS.
    • Non-infectious uveitis as per NICE TA460 (APCO September 2017).

Funded by specialised commissioning.

APCO July 2017. 

13.05.03 Adalimumab Humira®

For the treatment of:

    • Psoriasis as per NICE TA146 (APCO July 2008). For sequential use please refer to Clinical Commissioning Policy 266D (psoriasis) and Clinical Commissioning Policy 268A (psoriatic arthritis). 
    • Hidradenitis suppurativa as per NICE TA392 (APCO July 2016).
    • Plaque psoriasis in children and young people as per NICE TA455. Funded by specialised commissioning. (APCO September 2017).
13.06.01 Adapalene Differin®

For the treatment of acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

13.06.01 Adapalene with Benzoyl Peroxide Epiduo®

For the treatment of acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

A5.02.03 Adaptic® Touch 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Silicone step up dressing if other contact layers ineffective - can be used with VAC therapy. For more information, please see OCCG Wound Management Formulary and Guidance for Selecting Alternatives to Foams. 

APCO May 2015.

05.03.03.01 Adefovir Dipivoxil Hepsera®

Use by Consultant Hepatologist for oral Hepatitis B treatment only.

Not routinely commissioned by NHSE as per NICE CG165, IFR approval required.

APCO July 2011.

02.03.02 Adenosine 

Secondary care use only. 

03.04.03 Adrenaline / epinephrine Epipen®

Two injection devices should be prescribed and carried at all times to treat symptoms until medical assistance is available.

NB: Ensure that training is given to all patients, for all prescriptions, irrespective of whether patients have received or used the product previously. Prescribers should specify the brand to be dispensed.

From 1 October 2017 the Human Medicines (Amendment) Regulations 2017 will allow all schools to buy adrenaline auto-injector (AAI) devices without a prescription, for emergency use in children who are at risk of anaphylaxis but their own device is not available or not working (e.g. because it is broken, or out-of-date).

03.04.03 Adrenaline / epinephrine Intravenous

Hospital to supply epipen along with iron.

APCO January 2014.

02.07.03 Adrenaline / Epinephrine 1 in 10,000 (dilute) 
03.04.03 Adrenaline / Epinephrine 1 in 10,000 (dilute) 

Secondary care use only. 

03.04.03 Adrenaline / Epinephrine 1 in 1000 

Secondary care use only. 

03.01.05 Aerochamber Plus Flow-Vu spacer® 

Includes a visual tool that helps count breathes, assure correct use and delivery. For use in patients with carers (including children).

APCO May 2019. 

03.01.05 AeroChamber Plus® 

Second choice for patients who cannot manage with a volumatic® or if their inhalers do not fit a volumatic®. 

08.01.05 Afatinib Giotrif®

Red Traffic Light  For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310.

Funded by specialised commissioning.

APCO May 2014.

Black Traffic Light  For treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (Terminated appraisal NICE TA444).

APCO July 2017. 

11.08.02 Aflibercept Eylea®

For use by Consultant Ophthalmology in patients with;

  • Wet-age related macular degeneration as per NICE TA294. APCO September 2013.
  • Diabetic macular oedema as per NICE TA346. APCO September 2015.
  • Branch retinal vein occlusion as per NICE TA409. APCO November 2016. Also see Clinical Commissioning Policy 249B
  • Choroidal neovascularisation as per NICE TA486. APCO January 2018.

For sequential use please refer to Clinical Commissioning Policy 267S

04.03.04 Agomelatine Valdoxan®

Specialist prescribing only.

Fourth line treatment for Generalised Anxiety Disorder. See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017.

Also see Prescribing Guidelines for the Management of Moderate to Severe Depression.

APCO July 2017. 

05.05.01 Albendazole 

Secondary care use only. 

APCO July 2010.

08.02.04 Aldesleukin Proleukin®

Secondary care use only. 

08.01.05 Alectinib Alecensa®

Red Traffic Light For untreated ALK-positive advanced non-small-cell lung cancer as per NICE TA536. 

Funded by specialised commissioning.

APCO September 2018.

Black Traffic Light For previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NICE TA438 - terminated appraisal). 

APCO May 2017.

08.02.03 Alemtuzumab Lemtrada®

For the treatment of relapsing-remitting multiple sclerosis as per NICE TA312. 

Funded by specialised commissioning.

APCO July 2014.

06.06.02 Alendronic Acid 70mg tablets 

First line treatment for osteoporosis, see Guidance for Fracture Risk Assessment and Prevention in Primary Care.

APCO May 2018.

09.06.04 Alfacalcidol One-Alpha®

Suitable for prescribing in primary care following specialist recommendation.

A2.03.01 Alfamino® 

Suitable for continuation in primary care following initiation or recommendation from a specialist or dietitian only, for the management of Cow's milk protein allergy in children. Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

See:


APCO September 2017.

15.01.04.03 Alfentanil Rapifen®

For palliative care. To be continued in primary care after specialist recommendation and the receipt of a Patient Specific Protocol.

A5.03.01 Algivon®  

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

A5.03.01 Algivon® Plus 

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

A5.03.01 Algivon® Plus Ribbon 

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

03.04.01 Alimemazine Vallergan®

Second line to promethazine in both paediatric and dermatology patients.

02.12 Alirocumab Praluent®

For primary hypercholesterolaemia and mixed lipidaemia as per NICE TA393.

APCO July 2016.

13.05.01 Alitretinoin Toctino®

For prescribing by dermatologists only in secondary care. For the treatment of severe chronic hand eczema as per NICE TA177.

NB. Women of child-bearing potential should be on at least one, or preferably two, complementary forms of effective contraception (e.g. barrier and hormonal) for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. 

APCO September 2009.

A5.02.03 Allevyn® Life 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Please see OCCG Wound Management Formulary.

APCO May 2015.

10.01.04 Allopurinol 
04.07.04.01 Almotriptan Almogran®

For treatment of acute migraine if unaccetable side effects with first-line triptans, in line with Migraine: Acute Therapy Guidelines (Adult)

APCO November 2016. 

06.01.02.03 Alogliptin Vipidia▼®

Alogliptin is first choice DPP4i. See OCCG DPP4i switch protocol

APCO November 2018. 

06.01.02.03 Alogliptin and Metformin Vipdomet®

Alogliptin is first choice DPP4i. See OCCG DPP4i switch protocol

APCO November 2018. 

06.01.02.03 Alogliptin and Pioglitazone Incresync®

Alogliptin is first choice DPP4i. See OCCG DPP4i switch protocol

APCO November 2018. 

09.06.05 Alpha Tocopheryl Acetate 

Red Traffic Light  For advanced liver fibrosis associated with non-alcoholic fatty liver disease (NAFLD) as per NICE NG49.

APCO July 2016.

Amber Traffic Light  Suitable for prescribing in primary care following specialist recommendation for all other indications.

07.04.05 Alprostadil Caverject®

Brown Traffic Light  For erectile dysfuction in line with Clinical Commissioning Policy 41E.

APCO May 2016.

Black Traffic Light  For penile rehabilitation following prostate surgery in line with Clinical Commissioning Policy 233C.

APCO November 2012.

07.04.05 Alprostadil Viridal® Duo

Brown Traffic Light  For erectile dysfuction in line with Clinical Commissioning Policy 41E.

APCO May 2016.

Black Traffic Light  For penile rehabilitation following prostate surgery in line with Clinical Commissioning Policy 233C.

APCO November 2012.

07.04.05 Alprostadil MUSE®

Brown Traffic Light  For erectile dysfuction in line with Clinical Commissioning Policy 41E.

APCO May 2016.

Black Traffic Light  For penile rehabilitation following prostate surgery in line with Clinical Commissioning Policy 233C.

APCO November 2012.

01.01.01 Altacite plus® 

Restricted to Katharine House Hospice.

02.10.02 Alteplase Actilyse®

Specialist prescribing only.

02.10.02 Alteplase Actilyse Cathflo®

Specialist prescribing only.

A2.03.01 Althera® 

For the management of Cow's milk protein allergy in children, in line with:


Contains lactose and may be used if there is a palatability issue. Suitable from birth. 

Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

APCO September 2017.

A2.02.02.03 Altraplen Compact ®  

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

13.12 Aluminimum Chloride Hexahydrate 20% in Alcoholic Base Driclor®

For hyperhidrosis as per  Clinical Commissioning Policy 70C.

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

13.12 Aluminimum Salts Anhydrol® Forte

For hyperhidrosis as per  Clinical Commissioning Policy 70C.

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

12.01.01 Aluminium Acetate Ear drops 

Available as 8% and 13% ear drops for treatment of inflammation in otitis externa.

09.05.02.02 Aluminium Hydroxide Alu-Cap®

For use by Renal patients only. 

Suitable for prescribing in primary care following specialist recommendation.

01.01.01 Aluminium Only Preparations Alu-Cap®

For renal patients only. 

01.02 Alverine Spasmonal®
04.09.01 Amantadine 

Specialist initiation for Parkinson's Disease only.

05.01.04 Amikacin 

Secondary care use only. 

APCO July 2010.

02.02.03 Amiloride Hydrochloride 
03.01.03 Aminophylline Phyllocontin Continus®

Prescribe by brand.

See Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

03.01.03 Aminophylline IV 

Secondary care use only. 

05.01.09 Aminosalicylic acid Granupas®

Secondary care use only. 

APCO July 2010.

02.03.02 Amiodarone Hydrochloride   Secondary care use only.
02.03.02 Amiodarone Hydrochloride  

In line with Shared Care Protocol.

APCO May 2011.

04.02.01 Amisulpride 

Amber Traffic Light Suitable for continuation in primary care following specialist recommendation in line with Treatment of psychosis and schizophrenia algorithm

Restricted Item Brown Traffic Light  Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net

APCO September 2011.

04.03.01 Amitriptyline 

Consider SSRIs for treatment of depression. See Prescribing Guidelines for the Management of Moderate to Severe Depression.

Tricyclic antidepressants have similar efficacy to SSRIs but are more likely to be discontinued because of side-effects; toxicity in overdosage is also a problem.

04.07.03 Amitriptyline 

See Guidelines for the Management of Neuropathic Pain in Primary Care.

APCO March 2017.

04.07.04.02 Amitriptyline 

For prophylaxis of migraine in line with Migraine: Adult Prophylactic Therapy Guidelines. Unlicensed use. 

APCO January 2016.

02.06.02 Amlodipine 

First line calcium-channel blocker for hypertension.

Could be considered for the treatment of co-morbid hypertension / angina in patients with heart failure, see The Management of Heart Failure in Primary Care.

13.10.02 Amorolfine Loceryl®

Treatment for superficial onychomycosis (fungal nail infection) in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

05.01.01.03 Amoxicillin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.01.01.03 Amoxicillin 

Secondary care use only. 

APCO July 2010.

05.02 Amphotericin Fungizone®

Secondary care use only. 

APCO July 2010.

05.02 Amphotericin AmBisome®

Secondary care use only. 

APCO July 2010.

11.03.02 Amphotericin  

Secondary care (eye theatre) use only.

05.03.01 Amprenavir Agenerase®

For use by Infectious Diseases and Genito-urinary Medicine only.

Fosamprenavir is a pro-drug of amprenavir.

Funded by specialised commissioning.

APCO September 2005

09.01.04 Anagrelide Xagrid®

For second line use either after hydroxycarbamide failure or as an adjunct in those few cases where patients cannot tolerate a full dose of hydroxycarbamide.

To be used by Haematology consultant only.

APCO November 2007.

10.01.03 Anakinra Kineret®
  • For the treatment of juvenile idiopathic arthritis. Funded by specialised commissioning.
  • On the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of RA, except in the context of a controlled, long-term clinical study as per NICE CG79 (APCO May 2008).
  • Specialist prescribing only for Still's disease (APCO January 2020).
16.01 Anal Irrigation Systems 

Suitable for prescribing in primary care following specialist recommendation in line with Clinical Commissioning Policy 248.

08.03.04.01 Anastrozole 

Suitable for prescribing in primary care following

  • Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112In line with Endocrine Therapy in Breast Cancer Guidelines (APCO May 2007).
  • Genetics service recommendation for prevention of breast cancer in women at high and moderate risk of breast cancer as per NICE CG164 (APCO May 2018). 
14.05.03 Anti-D (Rh0) Immunoglobulin 

For routine antenatal anti-D prophylaxis for RhD-negative women as per NICE TA156.

02.11 Antihaemophilic Factor/von Willebrand Factor Complex Voncento®

Funded by specialised commissioning.

02.11 Antithrombin III Kybemin®

Specialist prescribing only.

Funded by specialised commissioning.

09.01.03 Antithymocyte Immunoglobulin (Rabbit)  

Secondary care use only for the treament of aplastic anaemia (adults and paediatrics).

Funded by specialised commissioning.

01.07.02 Anusol-HC 

Available to purchase over the counter, in line with Clinical Commissioning Policy 88D.

02.08.02 Apixaban Eliquis®

Green Traffic Light  For preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. See Primary Care Prescriber Decision Support for DOACs in Atrial Fibrillation.

APCO January 2017.

Amber Traffic Light  For treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.

APCO May 2015.

Brown Traffic Light For DVT (out of hours), in line with DVT service specification. Prescribe one off initial dose only if presentation of DVT outside of DVT clinic hours.

See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.

APCO September 2018.

Red Traffic Light  For preventing VTE after total hip or knee replacement in adults in line with NICE TA245.

APCO March 2012.

NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.

04.09.01 Apomorphine 

For Parkinson's disease in line with Shared Care Protocol.

APCO July 2012.

11.08.02 Apraclonidine Iopidine®

Red Traffic Light  For control or prevention of postoperative elevation of intra-ocular pressure after anterior segment laser surgery.

Amber Traffic Light  For continuation only following specialist recommendation as short-term adjunctive treatment of chronic glaucoma in patients not adequately controlled by another drug. May not provide additional benefit if patient already using two drugs that suppress the production of aqueous humour.

13.05.03 Apremilast Otezla®

For the treatment of:

    • Moderate to severe plaque psoriasis as per NICE TA419 (APCO January 2017).
    • Active psoriatic arthritis as per NICE TA433 (APCO March 2017).

 

04.06 Aprepitant Emend®

To prevent nausea and vomiting associated with highly emetogenic chemotherapy not responding to standard antiemetic therapy.

A2.03.01 Aptamil Pepti® 1 

For the management of Cow's milk protein allergy in children, in line with:


Contains lactose and may be used if there is a palatability issue. Suitable from birth to 6 months of age. 

Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

APCO September 2017.

A2.03.01 Aptamil Pepti® 2 

For the management of Cow's milk protein allergy in children, in line with:


Contains lactose and may be used if there is a palatability issue. Suitable from 6 months of age. 

Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

APCO September 2017.

16.01 Aquadeks 

For cystic fibrosis in children.

APCO March 2012.

01.06.03 Arachis Oil 

Do not give to patients with PEANUT ALLERGY.

Warm before use. 

02.08.01 Argatroban Exembol®

Secondary care use only. 

09.08.01 Arginine  

For the treatment of Urea Cycle Defects as per BIMDG adult emergency management guideline. 

To be initiated following discussion with Metabolic Medicine or as per patient’s care plan from the national centre.

04.02.01 Aripiprazole 

Red Traffic Light  For moderate to severe manic episodes in adolescents with bipolar disorder.

APCO September 2013.

Amber Traffic Light Suitable for continuation in primary care following specialist initiation for schizophrenia in people aged 15 to 17 years.

APCO May 2011.

Amber Traffic Light  Suitable for continuation in primary care following specialist recommendation in line with Treatment of psychosis and schizophrenia algorithm

APCO September 2004.

Restricted Item Brown Traffic Light  Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net

APCO September 2011.

04.02.01 Aripiprazole  

For secondary care psychiatrist prescribing only, in line with Treatment of psychosis and schizophrenia algorithm

04.02.01 Aripiprazole  

Only if recommended by secondary care in patients with swallowing difficulty or where supervised consumption is needed.

APCO November 2006.

04.02.02 Aripiprazole Abilify Maintena®

Secondary care psychiatrist prescribing only, in line with Treatment of psychosis and schizophrenia algorithm

APCO July 2013.

08.01.05 Arsenic Trioxide Trisenox®

For treating acute promyelocytic leukaemia as per NICE TA526.

APCO July 2018.

11.08.01 Artelac® night time gel 

Treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

NB. Lasts 6 weeks from opening.

05.04.01 Artemether with lumefantrine Riamet®

For malaria treatment.

05.04.01 Artesunate 

For severe falciparium malaria.

APCO July 2010.

12.03.05 AS saliva Orthana® 

Available as oral spray or lozenges. 

09.06.03 Ascorbic Acid Vitamin C
04.02.03 Asenapine 

Specialist prescribing only.

09.08.01 Asfotase alfa Strensiq®

For treating paediatric-onset hypophosphatasia as per NICE HST6.

Funded by specialised commissioning.

APCO September 2017.

02.09 Aspirin dispersible tablets 
04.07.04.01 Aspirin dispersible tablets 

For treatment of acute migraine, see Migraine: Acute Therapy Guidelines (Adult)

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

APCO November 2016. 

10.02 Ataluren Translarna®

For treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene.

Funded by specialised commissioning.

APCO September 2016.

05.03.01 Atazanavir Reyataz®

For use by Infectious Diseases and Genito-urinary Medicine only. 

Funded by specialised commissioning.

APCO September 2005.

02.04 Atenolol 
02.04 Atenolol 

Specialist prescribing only.

04.07.04.02 Atenolol 

For prophylaxis of migraine, see Migraine: Adult Prophylactic Therapy Guidelines

APCO January 2016. 

08.02.03 Atezolizumab Tecentriq®

Red Traffic Light For the treatment of:

  • Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable as per NICE TA492 (APCO January 2018).
  • Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy, as per NICE TA525 (APCO July 2018).
  • Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable, as per NICE TA492 (APCO September 2018).
  • Metastatic non-squamous non-small-cell lung cancer in combination with bevacizumab (Avastin), carboplatin and paclitaxel, as per NICE TA584 (APCO July 2019).

Funded by specialised commissioning.

 Black Traffic Light With carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer as per NICE TA618 (terminated appraisal). 

APCO March 2020. 

04.04 Atomoxetine Strattera®

For Attention Deficit Hyperactivity Disorder (ADHD) in line with Shared Care Protocol.

*Please note that adult patients will be discharged to primary care once stable as per Shared Care Protocol.

Also see:

APCO January 2018.

02.12 Atorvastatin 

Atorvastatin is the first line statin, usually at 20 mg for primary prevention and 40-80 mg for secondary prevention.

See Lipid Modification Guidance.

APCO September 2015.

05.04.08 Atovaquone Wellvone®

Secondary care use only. 

APCO July 2010.

15.01.05 Atracurium Besilate 

Specialist prescribing only.

A5.01.01 Atrauman® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

APCO May 2015. 

For more information, please see Guidance for Selecting Alternatives to Foams. 

11.05 Atropine 1% Eye drops 

Suitable for prescribing in primary care following specialist recommendation.

15.01.03 Atropine Sulfate  

Specialist prescribing only.

15.01.03 Atropine Sulfate Minijet®

Specialist prescribing only.

11.05 Atropine Sulphate single use Minims® Atropine Sulphate

Suitable for prescribing in primary care following specialist recommendation.

07.04.05 Avanafil Spedra®

Brown Traffic Light For erectile dysfunction in line with Clinical Commissioning Policy 41E.

APCO May 2016.

Black Traffic Light  For penile rehabilitation following prostate surgery in line with Clinical Commissioning Policy 233B.

08.01.05 Avelumab Bavencio®

For treating metastatic Merkel cell carcinoma, as per NICE TA517. 

Funded by specialised commissioning. 

APCO May 2018. 

07.04.05 Aviptadil + phentolamine Invicorp®

Brown Traffic Light  Second line treatment for erectile dysfunction equal to Caverject after oral therapies in line with Clinical Commissioning Policy 41E.

APCO July 2018.

Black Traffic Light  For penile rehabilitation following prostate surgery in line with Clinical Commissioning Policy 233B.

08.02.04 Axicabtagene ciloleucel  Yescarta®

For treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies as per NICE TA559.

Funded by specialised commissioning.

APCO March 2019.

08.01.05 Axitinib Inlyta®

For treating advanced renal cell carcinoma after failure of prior systemic treatment as per NICE TA333.

Funded by specialised commissioning.

APCO March 2015.

A2.02.01.02 Aymes® Shake 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

08.01.03 Azacitidine Vidaza®

Red Traffic Light  For the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia as per NICE TA218.

APCO May 2011.

Black Traffic Light  For acute myeloid leukaemia with more than 30% bone marrow blasts as per NICE TA399.

APCO September 2016.

Funded by specialised commissioning.

01.05.03 Azathioprine 

For inflammatory bowel disease in line with Shared Care Protocol.

APCO May 2011.

08.02.01 Azathioprine 

In line with Shared Care Protocol.

APCO March 2016.

10.01.03 Azathioprine 

In line with Shared Care Protocol for:

  • Inflammatory arthritis in line with
  • Rheumatology in children and adolescents

APCO March 2016.

13.05.03 Azathioprine 

In line with Shared Care Protocol.

APCO November 2011.

13.06.01 Azelaic Acid 15% gel Finacea®

For treatment of mild & localised papulopustular in line with  Guidelines for Antibiotic Prescribing in the Community 2018.

Second line treatment for acne vulgaris. 

APCO September 2018. 

05.01.05 Azithromycin 

Green Traffic Light  In line with Guidelines for Antibiotic Prescribing in the Community 2018.

Amber Traffic Light  For continuation in patients with cystic fibrosis.

APCO March 2003.

05.01.02.03 Aztreonam Azactam®

Secondary care use only. 

APCO July 2010.

10.02.02 Baclofen 
10.02.02 Baclofen 

For use by Neurology Consultants only.

APCO November 2007. 

10.01.03 Baricitinib Olumiant®

For treating moderate to severe rheumatoid arthritis as per NICE TA466.

APCO September 2017.

13.02.02 Barrier preparation Medi Derma-S® barrier film

Cheaper option than Cavilon®. To be used on 64cm2 (palm size) wound, in line with  OCCG Wound Management Formulary.

Also see Skin Barrier Management Pathway.

APCO March 2014 and APCO May 2015. 

13.02.02 Barrier preparation Medihoney® barrier cream

In line with OCCG Wound Management Formulary

Also see Skin Barrier Management Pathway.

APCO May 2015. 

13.02.02 Barrier preparation Medi Derma-S® barrier cream

Cheaper option than Cavilon®. See OCCG Wound Management Formulary.

Also see Skin Barrier Management Pathway.

APCO March 2014 and APCO May 2015. 

08.02.02 Basiliximab Simulect®

For renal transplant patients as per NICE TA481 and TA482.

Funded by specialised commissioning.

 APCO November 2017.

06.04.01.01 Bazedoxifene & conjugated oestrogens Duavive®

Suitable for continuation in primary care following specialist initiation if intolerant to progestogens, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO November 2017.

08.02.04 BCG bladder instillation OncoTICE®

Secondary care use only. 

08.02.04 BCG bladder instillation ImmuCyst®

Secondary care use only. 

14.04 BCG vaccine diagnostic agent 
14.04 BCG vaccine Intradermal 
06.01.01.03 BD Autoshield needles 

Brown Traffic Light Restricted for use by school staff for small number of primary school age children requiring insulin injections given by school staff and equipment supplied by GP (as per LEA agreement).

APCO September 2018. 

Black Traffic Light No GP prescribing, to be supplied by Oxford Health.

APCO November 2014.

06.01.01.03 BD Micro-Fine 

BD Viva and GlucoRx FinePoint are first-line choices for insulin pen needles.

APCO November 2016.

06.01.01.03 BD Viva 

BD Viva is first-line choice for insulin pen needles.

APCO November 2018.

03.02 Beclometasone Clenil Modulite®

First choice for CFC-free inhaled corticosteroid. 

Prescribe by brand as Clenil Modulite® and QVAR® brands of beclometasone inhalers are not dose equivalent.

For asthma see Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

03.02 Beclometasone Easyhaler®

Beclometasone easyhaler® should not be initiated for new patients for asthma.

People whose treatment with Beclometasone easyhaler® is not recommended in Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

Dry-powder inhaler available as 200micrograms per dose DPI.

03.02 Beclometasone and Formoterol Fostair®

For asthma see Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

03.02 Beclometasone and Formoterol Fostair NEXThaler®

For asthma see Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

Available as:

  • Beclometasone 100 microgram / Formoterol 6 microgram
  • Beclometasone 200 microgram / Formoterol 6 microgram

APCO September 2017.

03.02 Beclometasone and Formoterol Fostair®

Green Traffic Light  In line with Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

Restricted Item Brown Traffic Light  Restricted in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

12.02.01 Beclometasone Dipropionate 

Available to purchase over the counter for adults over 18s. 

See Clinical Commissioning Policy 88D.

05.01.09 Bedaquiline Sirturo®

Secondary care use only. 

03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

For the treatment of bee and wasp venom allergy a sper NICE TA246.

APCO March 2012.

08.02.02 Belatacept Nulojix®

Red Traffic Light  To prevent rejection in bowel transplant patients who have demonstrable tacrolimus nephrotoxicity.

Funded by specialised commissioning.

Black Traffic Light  Not recommended for renal transplant patients as per NICE TA481 and TA482.

APCO November 2017.

10.01 Belimumab Benlysta®

For the treatment of active autoantibody-positive systemic lupus erythematosus as per NICE TA397.

Funded by specialised commissioning.

APCO July 2016.

08.01.01 Bendamustine Levact®

Red Traffic Light 

  • For the first-line treatment of chronic lymphocytic leukaemia as per NICE TA216 (APCO May 2011).
  • In combination with obinutuzumab for treating follicular lymphoma refractory to rituximab, as per NICE TA472 (APCO November 2017). Funded by specialised commissioning. 

Black Traffic Light 

  • For the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab as per NICE TA206 (APCO September 2010).
  • In combination with ibrutinib and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (NICE TA437 - terminated appraisal). APCO May 2017.
02.02.01 Bendroflumethiazide 
03.04.02 Benralizumab Fasenra®

For treating severe eosinophilic asthma as per NICE TA565.

Funded by specialised commissioning.

APCO May 2019.

15.02 Benzocaine 3% 

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

13.06.01 Benzoyl Peroxide 4% cream Brevoxyl®

For treatment of acne vulgaris in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Available to purchase over the counter. 

 

13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily

For the treatment of acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

12.03.01 Benzydamine Difflam®

Available as oromucosal spray and mouthwash. Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

05.01.01.01 Benzylpenicillin Benzathine 

Secondary care use only. 

APCO July 2010.

05.01.01.01 Benzylpenicillin Sodium  

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

 

04.06 Betahistine Dihydrochloride 

For treatment of vertigo, tinnitus and hearing loss associated with Ménière's disease.

06.03.02 Betamethasone Betnesol®

Specialist prescribing only.

06.03.02 Betamethasone Betnesol®
13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid Diprosalic®

Available in ointment and scalp application. 

Potent

13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®

For moderate eczema (larger quantities), in line with Guidelines for the use of Corticosteroids in Atopic Eczema.

Moderately potent

13.04 Betamethasone (as Valerate) 0.1% Betnovate®

For severe eczema, in line with Guidelines for the use of Corticosteroids in Atopic Eczema. Also available as scalp application, and lotion.

Prescribe as Betnovate® as currently more cost effective than generic. 

Potent

13.04 Betamethasone (as Valerate) 0.1% with Clioquinol 3% 

Used to be marketed under the brand name Betnovate-C® cream and ointment - now only available generically.

Potent with antimicrobial

13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® Cream

Only CREAM is available at OUH Trust.

Potent with antimicrobial

13.04 Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% 

Was Betnovate-N® but now only available generically. 

Note: Only cream is available at OUH Trust.

 Potent with antimicrobial

11.04.01 Betamethasone 0.1% Betnesol®

Suitable for prescribing in primary care following specialist recommendation.

12.01.01 Betamethasone 0.1% Betnesol®, Vistamethasone®

0.1% drops for ear, eye, or nose. 

12.01.01 Betamethasone 0.1% with Neomycin 0.5% ear drops Betnesol N®
11.04.01 Betamethasone 0.1% with Neomycin 0.5% Eye drops Betnesol N®

Suitable for prescribing in primary care following specialist recommendation.

13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® Cream

Useful for vulval dermatoses.

Potent with antifungal

12.02.01 Betamethasone Sodium Phosphate 
12.03.01 Betamethasone Soluble tablets 

For oral ulceration (unlicensed indication) in adult and child over 12 years. Usual dose is 500 micrograms dissolved in 20 mL water and rinsed around the mouth 4 times daily.

07.04.01 Bethanechol Chloride Myotonine®
08.01.05 Bevacizumab Avastin®

Red Traffic Light  For ovarian cancer (as per Bevacizumab Extended Access Program) and neurofibromatosis type 2 (off-label use).

Black Traffic Light

    • First-line for the treatment of advanced and/or metastatic renal cell carcinoma as per NICE TA178.
    • Diabetic macular oedema (APCO January 2012).
    • Macular oedema caused by retinal vein occlusion (APCO January 2012).
    • Metastatic colorectal cancer after first line chemotherapy as per NICE TA242.
    • First-line treatment of metastatic breast cancer as per NICE TA214.
    • In combination with capecitabine. First line treatment of metastatic breast cancer as per NICE TA263.
    • In combination with gemcitabine and carboplatin for first recurrence of platinum-sensitive advanced ovarian cancer as per NICE TA285.
    • In combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for treatment of metastatic colorectal cancer as per NICE TA212.
    • In combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer as per NICE TA284.
    • Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (NICE TA353 - terminated appraisal).
    • Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (NICE TA436 - terminated appraisal). APCO May 2017. 

 

08.01.05 Bevacizumab Avastin®

Red Traffic Light  For ovarian cancer (as per Bevacizumab Extended Access Program) and neurofibromatosis type 2 (off-label use).

Black Traffic Light

    • First-line for the treatment of advanced and/or metastatic renal cell carcinoma as per NICE TA178.
    • Diabetic macular oedema (APCO January 2012).
    • Macular oedema caused by retinal vein occlusion (APCO January 2012).
    • Metastatic colorectal cancer after first line chemotherapy as per NICE TA242.
    • First-line treatment of metastatic breast cancer as per NICE TA214.
    • In combination with capecitabine. First line treatment of metastatic breast cancer as per NICE TA263.
    • In combination with gemcitabine and carboplatin for first recurrence of platinum-sensitive advanced ovarian cancer as per NICE TA285.
    • In combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for treatment of metastatic colorectal cancer as per NICE TA212.
    • In combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer as per NICE TA284.
    • Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (NICE TA353 - terminated appraisal).
    • Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (NICE TA436 - terminated appraisal). APCO May 2017. 

 

11.08.02 Bevacizumab 

For neo-vascularisation in non wet-AMD conditions and glaucoma prior to laser treatment.

02.12 Bezafibrate 

Decision to start a fibrate should be made in conjunction with specialist advice oxon.diabetes_lipidsadvice@nhs.net.

See Lipid Modification Guidance.

A5.02.04 Biatain® Super 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

Not to be used under bandages - super absorbent. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

08.03.04.02 Bicalutamide 

Suitable for continuation in primary care following initiation in secondary care by urology or oncology.

11.06 Bimatoprost 0.01% Eye drops Lumigan®

Third line choice in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

NB. The 0.03% drops were discontinued at the end of April 2015.

APCO March 2018.

11.06 Bimatoprost 0.03% preservative free 

Third line if preservative-free treatment required in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Bimatoprost with Timolol Ganfort®

For patients intolerant or who have allergies to the preservative containing preparations only in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

Suitable for prescribing in primary care following specialist recommendation.

NB. Fixed combination product is cheaper for preservative free Ganfort(r) than individual component.

APCO March 2018.

11.06 Bimatoprost with Timolol Ganfort®

Suitable for prescribing in primary care following specialist recommendation, in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

12.03.05 Biotene Oralbalance® 

Saliva replacement gel. 

09.08.01 Biotin  

Secondary care use only for children with metabolic disorders.

Prescribed by Paediatric Neurologists only.

APCO September 2013.

06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix50

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 25

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 50

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Isophane Insulin Hypurin® Porcine 30/70 Mix

Consider asking for specialist review-unusual regime to use.

06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 15

Green Traffic Light  Patients with Type 1 Diabetes are more likely to achieve tight glucose control with a combination of basal and bolus insulin rather than mixed insulin.  Mixed insulin should be reserved for patients who cannot tolerate multiple injections or in whom a trial of multiple injections has resulted in significant hypoglycaemia.

Patients with type 1 diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

01.06.02 Bisacodyl Dulcolax®

Available to purchase over the counter.

01.03.03 Bismuth subsalicylate Pepto-Bismol®

Liquid and tablet preparations - available to purchase over the counter. 

For eradication of Helicobacter pylori, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018.

NB. Liquid is black-listed in drug tariff. 

02.04 Bisoprolol 

First line for secondary prevention of coronary atery disease (e.g. post STEMI/NSTEMI).

First line choices of beta blockers for heart failure. See The Management of Heart Failure in Primary Care.

09.05.01.02 Bisphosphonates 

Secondary care use only for the treatment of hypercalcaemia.

02.08.01 Bivalirudin Angiox®

For the treatment of ST-segment-elevation myocardial infarction as per NICE TA230.

08.01.02 Bleomycin 

For treatment of vascular malformations in patients unable to receive sodium tetradecyl sulfate (STS).

APCO July 2008.

08.02 Blinatumomab Blincyto®
  • For previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia as per NICE TA450 (APCO July 2017).
  • For treating acute lymphoblastic leukaemia in remission with minimal residual disease activity as per NICE TA589 (APCO September 2019).

Funded by specialised commissioning.

 

06.01.06 Blood glucose test strip Accu-Chek® Active

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Palmdoc® iCare Advanced Solo

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Glucomen® GM

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoMen® Visio Sensor

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoMen® Sensor

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip FreeStyle®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip WaveSense JAZZ® Duo

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoLab®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Microdot®+

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip SURESIGN Resure®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Mendor Discreet®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Betachek C50®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip FineTouch®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Glucoflex-R®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Advocate® Redi-Code+

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip BGStar®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Dario® Lite

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GluNEO®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip One Touch® Vita

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip On-Call Advanced®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Mylife Pura®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Mylife Unio®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoDock® Glucose

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Element®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip TRUEresult®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip TRUEyou®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip TEE2®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip SD Codefree®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip SuperCheck Plus®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip VivaChek Ino®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Betachek G5®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Compact 3®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Finetest Lite®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoZen.auto®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip i-Health®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip MODZ®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Betachek Visual®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip AutoSense®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip CareSens® N

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip CareSens® Pro

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip eBchek®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoNavii® Glucose

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoRx Go®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip MediTouch®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip MediTouch 2®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Accu-Chek® Aviva

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Accu-Chek® Performa

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip SuperCheck2®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoMen® LX Sensor

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoMen® Areo Sensor

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoRx Nexus®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoRx® HCT

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Palmdoc® iCare Advanced

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip IME-DC®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Omnitest® 5

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Sensorcard®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip MyGlucoHealth®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip GlucoRx Q®

Formerly GlucoRx Original Strips. 

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

 

06.01.06 Blood glucose test strip MediSense® SoftSense

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip One Touch® Verio

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip One Touch Ultra®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Breeze 2®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Contour® TS

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Contour®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Accu-Chek® Mobile

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip FreeStyle Lite®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip FreeStyle Optium®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Dario®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip WaveSense JAZZ®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip One Touch Select® Plus

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Palmdoc®

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip TrueTrack® System

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Omnitest® 3

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

06.01.06 Blood glucose test strip Contour® Next

First line test strip is Finetest Lite. Other blood glucose meters with strips costing <£6 for 50 can also be considered first line.

Clinicians are encouraged to use cost-effective options unless there is a clear need to use other meters. See guidance on Choosing a Blood Glucose Monitoring Meter and Guideline for Blood Glucose Monitoring

APCO May 2019.

05.03.03.02 Boceprevir Victrelis®

For the treatment of genotype 1 chronic hepatitis C as per NICE TA253.

Funded by specialised commissioning.

APCO May 2012.

14.04 Boostrix-IPV 

Contains: Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)

13.08.01 Borderline Substances Anthelios® XL SPF 50+ Melt - in cream

For specific ACBS conditions in line with Sunscreen Policy:

    • Abnormal cutaneous photosensitivity resulting from genetic disorder –albinism, xeroderma pigmentosum.
    • Vitiligo.
    • Photodermatoses resulting from radiotherapy.
    • Lupus, both cutaneous and systemic.



APCO May 2016.

08.01.05 Bortezomib Velcade®

Red Traffic Light  For the treatment of:

  • Multiple Myeloma as per NICE TA129, TA228 and TA311 (APCO September 2011).
  • Mantel cell lymphoma as per NICE TA370 (APCO January 2016).

Black Traffic Light  For treating multiple myeloma after second or subsequent relapse NICE TA453 (terminated appraisal).

APCO September 2017.

08.01.05 Bosutinib Bosulif®

For previously treated chronic myeloid leukaemia as per NICE TA401.

APCO September 2016.

Black Traffic Light Not recommended for untreated chronic myeloid leukaemia as per NICE TA576 (terminated appraisal).

APCO May 2019.

07.04.02 Botulinum Toxin A  

In line with Clinical Commissioning Policy 254A

16.01 Botulinum Toxin A Xeomin®

For treating chronic sialorrhoea in line with NICE TA605.

Also see Clinical Commissioning Policy 254A.

APCO November 2019.

04.07.04.02 Botulinum Toxin Type A 

Red Traffic Light  Secondary care use only for chronic migraine in line with Migraine: Adult Prophylactic Therapy Guidelines and Clinical Commissioning Policy 254A

APCO January 2016.

04.09.03 Botulinum Toxin Type A 

Red Traffic Light  For spasticity in line with Clinical Commissioning Policy 254A.

Black Traffic Light  For Long term Bell’s Palsy and Sialorrhoea (Severe Drooling): Not normally funded due to lack of high quality evidence of clinical and cost effectiveness, in line with Clinical Commissioning Policy 254A

14.04 Botulism antitoxin 

Secondary care use only:

  • Contains specific antitoxic globulins that have the power of neutralising the toxins formed by types A,B & E of Clostridium Botulinum.
  • For post-exposure prophylaxis of botulism and for the treatment of persons thought to be suffering from botulism.

01.06.05 Bowel Cleansing Solutions Citramag®

Secondary care use only.

08.01.05 Brentuximab vedotin Adcetris®

Red Traffic Light For the treatment of:

  • Relapsed or refractory systemic anaplastic large cell lymphoma as per NICE TA478 (APCO November 2017).
  • CD30-positive Hodgkin lymphoma as per NICE TA524 (APCO July 2018). 
  • CD30-positive cutaneous T-cell lymphoma in line with NICE TA577 (APCO July 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for untreated advanced Hodgkin lymphoma in line with NICE TA594 (terminated appraisal).

APCO September 2019.

08.01.05 Brigatinib Alunbrig®

For treating ALK-positive advanced non-small-cell lung cancer after crizotinib as per NICE TA571.

Funded by specialised commissioning.

APCO May 2019.

13.06.01 Brimonidine gel Mirvaso®

For predominant erythema in acne rosacea, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

11.06 Brimonidine Tartrate 0.2% Eye drops Alphagan®

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan®

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Brinzolamide Azopt®

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza®

Suitable for prescribing in primary care following specialist recommendation. For patients in which beta blockers are contraindicated and combination product indicated.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Brinzolamide with timolol Azarga®

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

04.08.01 Brivaracetam Briviact®

Suitable for continuation in primary care following initiation by Epileptologists only.

For pharmacoresistant partial seizures in patients who have failed treatment with at least 3 drugs and are not on levetiracetam. Brivaracetam will be adjunctive therapy with the aim of replacing one of the patient's pre-existing anti-epileptic drugs. 

APCO March 2017.

13.05.03 Brodalumab Kyntheum®

For treating moderate to severe plaque psoriasis, as per NICE TA511. 

 APCO May 2018. 

11.08.02 Bromfenac Yellox®

For post-cataract extraction in patients at high risk of developing cystoid macular oedema (CMO).

APCO November 2013.

04.09.01 Bromocriptine 

Suitable for continuation in primary care following specialist initiation.

06.07.01 Bromocriptine 

Suitable for continuation in primary care following specialist initiation.

01.05.02 Budesonide Cortiment MMX®

Alternative to prednisolone if not tolerated (at the second line stage of treatment for UC). OUH will provide initial 8 week course but further courses may be requested for GP to prescribe for repeat flare up or via IBD advice line.

Must be brand specific prescribing.

Clinic/ IBD advice line should send specific prescribing information to GPs if requested (email template to be developed).

APCO November 2018.

01.05.02 Budesonide Budenofalk®

Suitable for prescribing in primary care following recommendation from gastroenterology only. 

Prescribe by brand name.

03.02 Budesonide Pulmicort®

For asthma see Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

03.02 Budesonide and Formoterol Symbicort® Turbohaler

Green Traffic Light  For management of asthma as per Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

Restricted Item Brown Traffic Light  Restricted in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

03.02 Budesonide and Formoterol Symbicort®

Restricted with in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

02.02.02 Bumetanide 

May be more effective in patients with heart failure who are severely oedematous. See The Management of Heart Failure in Primary Care. 

15.02 Bupivacaine and Adrenaline 

Specialist prescribing only.

15.02 Bupivacaine hydrochloride Marcain®

Specialist prescribing only.

15.02 Bupivacaine Hydrochloride 

Specialist prescribing only.

15.02 Bupivacaine Hydrochloride with Glucose Marcain Heavy®

Specialist prescribing only.

04.07.02 Buprenorphine Hapoctasin® 72-hourly patch

Suitable for prescribing in primary care following specialist recommendation as per Opioid Prescribing Guidelines for Non Cancer Pain.

Only for patients with stable persistent pain who have swallowing difficulties or cannot tolerate other options. Not to be used for any other patient group.

APCO September 2015. 

04.07.02 Buprenorphine Bunov® 7-day patch

First choice brand of buprenorphine patches (replacing Butec). To be used on specialist recommendation only, in line with Opioid Prescribing Guidelines for Non Cancer Pain.

Only for patients with stable persistent pain who have swallowing difficulties or cannot tolerate other options. Not to be used for any other patient group.

APCO March 2019. 

04.07.02 Buprenorphine Transtec® 96-hourly patch

Suitable for prescribing in primary care following specialist recommendation as per Opioid Prescribing Guidelines for Non Cancer Pain.

Only for patients with stable persistent pain who have swallowing difficulties or cannot tolerate other options. Not to be used for any other patient group.

APCO September 2015. 

04.10.03 Buprenorphine 

For substance misuse refer patients to Oxfordshire Drug and Alcohol recovery service (Turning Point).

Referrals to Turning Point can be made via a dedicated form on GP Proforma Practice systems.

They also accept self-referrals from professionals, organisations, individuals and concerned family members or friends, using the referral form available on their website.

Contact details:


APCO July 2011.

04.10.02 Bupropion Hydrochloride Zyban®

Only to be provided as part of SLA from the new smoking cessation provider.

APCO March 2018.

10.01.03 Burosumab Crysvita®

For treating X-linked hypophosphataemia in children and young people as per NICE HST8.

Funded by specialised commissioning.

APCO November 2018.

04.01.02 Buspirone Hydrochloride 

Suitable for continuation in primary care following specialist initiation for Generalised Anxiety Disorder. See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017.

NB. Buspiron is not available at the OUH Trust.

08.01.01 Busulfan 

Secondary care use only. 

APCO July 2008.

08.01.05 Cabazitaxel Jevtana®

For hormone-refractory metastatic prostate cancer previously treated with a docetaxel as per NICE TA391.

APCO July 2016.

04.09.01 Cabergoline Cabaser®

Suitable for continuation in primary care following specialist initiation.

06.07.01 Cabergoline 

Suitable for continuation in primary care following specialist initiation.

08.01.05 Cabozantinib Cometriq®

Red Traffic Light For treating medullary thyroid cancer, as per NICE TA516.

Funded by specialised commissioning.

APCO May 2018. 

Black Traffic Light Not recommended for previously treated advanced hepatocellular carcinoma as per NICE TA582 (terminated appraisal). 

APCO July 2019.

08.01.05 Cabozantinib Cabometyx®

For treating

  • Previously treated advanced renal cell carcinoma as per NICE TA463 (APCO September 2017).
  • Untreated advanced renal cell carcinoma as per NICE TA542 (APCO November 2018).

Funded by specialised commissioning.

 

09.05.01.01 Cacit® 

For patients with feeding tubes only.

Suitable for prescribing in primary care following specialist recommendation.

13.03 Calamine 

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

NB. Calamine Oily lotion contains arachis (peanut) oil.

09.05.01.01 Calcichew® 

Suitable for prescribing in primary care following specialist recommendation.

13.05.02 Calcipotriol 

Ointment 50micrograms/g (~£6 per 30g)
Scalp solution 50micrograms/mL (~£57 per 60ml)

NB. Only OINTMENT is available at OUH.

13.05.02 Calcipotriol 50mcg/g with Betamethasone 0.05% Enstilar® Foam

Enstilar® Foam should only be used in line with local pathway (in development) and NICE guideline for Psoriasis (CG153) as a third or fourth line treatment.

 APCO November 2017. 

09.06.04 Calcitriol 

Suitable for prescribing in primary care following specialist recommendation.

13.05.02 Calcitriol 3micrograms/g Silkis®

Use in line with Psoriasis pathway only  - 2nd line option for vulva.

APCO May 2018. 

09.05.02.02 Calcium Acetate Phosex®

Suitable for prescribing in primary care following specialist recommendation.

09.05.02.02 Calcium Acetate Renacet®

Addition to formulary in addition to Phosex. Phosex supply difficulties due to limitation of suppliers to pharmacies.

APCO September 2018. 

09.05.02.02 Calcium Carbonate Calcichew®

Suitable for prescribing in primary care following specialist recommendation.

09.05.01.01 Calcium Chloride 

Secondary care use only. 

08.01 Calcium Folinate 

Secondary care use only. 

APCO July 2008.

09.05.01.01 Calcium Gluconate 

Secondary care use only. 

08.01 Calcium Levofolinate Isovorin®

Secondary care use only. 

APCO July 2008.

06.01.02.03 Canagliflozin Invokana▼®

Second line option SGLT2i - consider discussion with specialist team.

See SGLT2i checklist, patient information leaflet on DKA risk and OCCG letter to clinicians.

APCO November 2018.

06.01.02.03 Canagliflozin and Metformin Vokanamet®

Second line option SGLT2i - consider discussion with specialist team.

See SGLT2i checklist, patient information leaflet on DKA risk and OCCG letter to clinicians.

APCO November 2018.

02.05.05.02 Candesartan 

Candesartan is the preferred Angiotensin II receptor antagonist for patients intolerant of ACE inhibitors due to cough.

For heart failure, see The Management of Heart Failure in Primary Care.

04.07.04.02 Candesartan  

For prophylaxis of migraine, see Migraine: Adult Prophylactic Therapy Guidelines.

APCO January 2016. 

02.09 Cangrelor Kengrexal®

Red Traffic Light Specialist prescribing only for Percutaneous Coronary Intervention (PCI). Funded by specialised commissioning. 

APCO September 2019.

Black Traffic Light For reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy as per NICE TA351 (terminated appraisal).

APCO September 2015.

 

13.09 Capasal® 

Available to purchase over the counter for treatments of seborrheic dermatitis or psoriasis in line with Clinical Commissioning Policy 88D.

08.01.03 Capecitabine Xeloda®

For the treatment of:

  • Colorectal cancer as per NICE TA61 and TA100 
  • Gastric cancer as per NICE TA191
  • Breast cancer as per NICE CG81

APCO July 2008.

12.03.01 Caphosol® 

Oral rinse or dispersible tablets for the treatment of oral mucositis in oncology.

Caphosol® is classed as a medical device.

09.01.04 Caplacizumab 

Secondary care use only for acquired thrombotic thrombocytopenic purpura, via patient access scheme. Approved at MMTC.

APCO May 2019.

05.01.09 Capreomycin Capastat®

For tuberculosis resistant to first-line drugs, in combination with other drugs.

APCO July 2012.

A2.03.01 Caprilon® 

MCT enhanced formula for children with disorders in which a high intake of MCT is beneficial.

Suitable for continuation in primary care following initiation or recommendation from a specialist or dietitian only.

10.03.02 Capsaicin Cream Axsain®

Restricted in line with Guidelines for the Management of Neuropathic Pain in Primary Care.

APCO March 2017.

02.05.05.01 Captopril 

Restricted for paediatric use.

04.02.03 Carbamazepine 

Suitable for continuation in primary care following specialist recommendation.

04.08.01 Carbamazepine 

Suitable for continuation in primary care following specialist initiation or recommendation.

06.02.02 Carbimazole 

First line treatment for hyperthyroidism. See Management Guidelines - Thyroid Disease. 

03.07 Carbocisteine 
11.08.01 Carbomer 980 Clinitas® gel or Geltears®

Second line treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

11.08.01 Carbomers 980 Viscotears® Unit dose

Restricted for patients who require a preservative formulation, in line with Ocular lubricant prescribing guidelines.

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018. 

07.01.01 Carboprost Hemabate®

Secondary care use only. 

08.01.05 Carfilzomib Kyprolis®

For previously treated multiple myeloma as per NICE TA457.

Funded by specialised commissioning.

APCO September 2017.

04.02.01 Cariprazine 

Secondary care use only. 

11.08.01 Carmellose 0.5% eye drops Optive®

 Third line treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

11.08.01 Carmellose preservative-free Celluvisc® 1.0% unit doses eye drops

Restricted for patients who require a preservative formulation, in line with Ocular lubricant prescribing guidelines.

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018. 

08.01.01 Carmustine Gliadel®

Red Traffic Light  For the treatment of newly diagnosed high-grade glioma as per NICE TA121.

Black Traffic Light  For the treatment of recurrent glioblastoma multiforme as per NICE TA149 (terminated appraisal).

APCO September 2010.

A2.05.02 Carobel, Instant®  

In line with ACBS condition.

APCO January 2019.

02.04 Carvedilol 

First line choices beta blocker for heart failure. See The Management of Heart Failure in Primary Care.

07.04.04 Catheter Patency Solutions 

Brands include Uro-Tainer Chlorhexidine®.

07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 

Contains Citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8% and disodium edetate 0.01%. Brands include OptiFlo R®, Uriflex R®, and Uro-Tainer® Twin Solutio R. 

05.01.02.01 Cefalexin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.01.02.01 Cefazolin 

Micro ID use only for Staph infections.

APCO September 2018.

 

05.01.02.01 Cefixime Suprax®

For continuation only when started in secondary care.

05.01.02.01 Cefotaxime 

Secondary care use only. 

APCO July 2010.

05.01.02.01 Cefoxitin 

For the treatment of non-tuberculous mycobacteria (NTM) in adult patients with cystic fibrosis.

APCO July 2010.

05.01.02.01 Ceftazidime 

Secondary care use only. 

APCO July 2010.

05.01.02 Ceftazidime and Avibactam Zavicefta®

Specialist prescribing only. 

APCO July 2017. 

05.01.02 Ceftolozane & tazobactam Zerbaxa®

Specialist prescribing only.

APCO July 2017.

05.01.02.01 Ceftriaxone 

Secondary care use only. 

APCO July 2010.

05.01.02.01 Cefuroxime 

Secondary care use only. 

APCO July 2010.

10.01.01 Celecoxib 

For use in osteoarthritis and rheumatoid arthritis as per NICE guidelines only.

Onsenal® was withdrawn from the market in August 2011.

08.02.03 Cemiplimab Libtayo®

For treating metastatic or locally advanced cutaneous squamous cell carcinoma as per NICE TA592.

Funded by specialised commissioning. 

APCO September 2019.

08.01.05 Ceritinib Zykadia®

For:

  • Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer as per NICE TA395 (APCO July 2016).
  • Untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults as per NICE TA500 (APCO March 2018).
16.01 Cerliponase alpha Brineura®

For treating neuronal ceroid lipofuscinosis type 2. Funded by specialised commissioning.

APCO January 2020.

10.01.03 Certolizumab Pegol Cimzia®

For treating:

  • Rheumatoid arthritis as per NICE TA186 (APCO March 2016).
  • Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor as per NICE TA415 (APCO November 2016).
  • With secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs as per NICE TA 445 (APCO July 2017). Funded by specialised commissioning.
  • For treating moderate to severe plaque psoriasis as per NICE TA574 (APCO May 2019). 

Also see Clinical Commissioning Policy 201D.

03.04.01 Cetirizine 

Available to purchase over the counter.

Only prescribe if required on a continuous basis for chronic rhinosinusitis and chronic urticaria, in line with Clinical Commissioning Policy 88D

For spontaneous urticaria in line with Management Guideline for Spontaneous Urticaria with/without Angioedema in Adults

13.11.03 Cetrimide 

For skin disinfection.

Ingredient of Tisept® and Travasept® 100.

08.01.05 Cetuximab Erbitux®

Red Traffic Light  For the treatment of:

  • Locally advanced squamous cell cancer of the head and neck as per NICE TA145.
  • Previously untreated metastatic colorectal cancer in combination with panitumumab as per NICE TA439 (APCO May 2017). 
  • Recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA473 (APCO November 2017).

Funded by specialised commissioning. 

Black Traffic Light  For the treatment of:

  • Recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA172 (APCO July 2009).
  • Metastatic colorectal cancer after first-line chemotherapy as per NICE TA242 (APCO March 2012).
04.01.01 Chloral Hydrate 

Secondary care use only. 

08.01.01 Chlorambucil Leukeran®

Secondary care use only. 

APCO July 2008.

05.01.07 Chloramphenicol 

Secondary care use only. 

APCO July 2010.

11.03.01 Chloramphenicol 

Treatment for conjunctivitis if severe, as most are viral or self-limiting. Mild cases should not need treating. They are usually unilateral with yellow-white mucopurulent discharge.

Available to purchase over the counter for patients over 2 years of age. 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

12.01.01 Chloramphenicol 

Available as 5% or 10% ear drops. 

04.01.02 Chlordiazepoxide 

For the treatment of Acute Alcohol Withdrawal. Suitable for continuation in primary care following specialist recommendation.

13.11.02 Chlorhexidine 0.015% with Cetrimide 0.15% Tisept®

To be used undiluted for general skin disinfection and wound cleansing.

11.03.01 Chlorhexidine 0.02% Eye drops 

Secondary care use only for the treatment of Acanthamoeba keratitis.

13.11.02 Chlorhexidine 0.5% Hibi® Liquid Hand Rub+

To be used undiluted for hand and skin disinfection.

13.11.02 Chlorhexidine 4% solution 

For pre-operative hand and skin preparation and for general hand disinfection.

Brands include Hydrex® surgical scrub and Hibiscrub® cleansing solution. Can be purchased over the counter.

 

12.03.04 Chlorhexidine gluconate Corsodyl®

Available as 0.2% mouthwash, 0.2% oral spray and 1% dental gel. 

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

 

12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®

Contains arachis (peanut) oil so should not be used in patients with a peanut allergy.

13.11.02 Chlorhexidine Solution 2.5% (≡ Chlorhexidine 0.5%) (Alcoholic) 

For pre-operative skin disinfection.

08.01.01 Chlormethine Hydrochloride 

Secondary care use only. 

APCO July 2008.

05.04.01 Chloroquine Avloclor®

Red Traffic Light  For malaria treatment.

Black Traffic Light  For prophylaxis of malaria.

APCO July 2010.

05.04.01 Chloroquine Nivaquine®

Red Traffic Light  For malaria treatment.

Black Traffic Light  For prophylaxis of malaria.

APCO July 2010.

02.02.01 Chlorothiazide 250mg/5ml liquid 

Restricted to neonates and paediatric patients with swallowing difficulties.

Available as an unlicensed product.

03.04.01 Chlorphenamine Maleate Piriton®

Available to purchase over the counter.

Only prescribe if required on a continuous basis for chronic rhinosinusitis and chronic urticaria, in line with Clinical Commissioning Policy 88D

04.02.01 Chlorpromazine 

Suitable for continuation in primary care following specialist recommendation.

04.06 Chlorpromazine 

For nausea and vomiting of terminal illness (where other drugs have failed or are not available).

14.04 Cholera vaccine Dukoral®
12.03.01 Choline Salicylate Bonjela® Adult

Available to purchase over the counter, in line with Clinical Commissioning Policy 88D.

To be used in over 16s only. 

06.05.01 Choriogonadotropin Alfa Ovitrelle®

Specialist prescribing only for treatment of male infertility.

GPs should not prescribe any fertility drugs as per Clinical Commissioning Policy 11G.

APCO November 2018.

A5.04.02 Cica-Care® 

Please liaise with specialist service e.g. plastics TV for support. 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Please see OCCG Wound Management Formulary.

APCO May 2015.

03.02 Ciclesonide Alvesco®

For patients who require an inhaled corticosteroid, who have unacceptable side effects caused by standard and high dose corticosteroid despite thorough post-dose mouth rinsing, use of a spacer and treatment of candidiasis.

See Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

01.05.03 Ciclosporin 

*Ciclosporin must be prescribed by BRAND NAME.*

For induction and remission of ulcerative colitis (unlicensed) in line with Shared Care Protocol.

APCO May 2015.

08.02.02 Ciclosporin 

*Ciclosporin must be prescribed by BRAND NAME.*

Used as a second-line therapy (unlicensed) for a range of neurological disorders in line with Shared Care Protocol including:

    • Myasthenia gravis
    • Inflammatory myopathies and neuropathies
    • Vasculitis and other immune-mediated central and peripheral nervous system diseases



APCO May 2015.

08.02.02 Ciclosporin 

*Ciclosporin must be prescribed by BRAND NAME.*

For all renal patients, supply will be provided in secondary care.

APCO May 2015.

10.01.03 Ciclosporin 

*Ciclosporin must be prescribed by BRAND NAME.*

In line with Shared Care Protocol for the treatment of:

  • Rheumatoid arthritis
  • Psoriatic arthritis, Behcet’s disease, myositis, systemic lupus erythematosus (all unlicensed)
  • In combination with other DMARDs such as methotrexate with careful monitoring.

APCO May 2015.

11.99.99.99 Ciclosporin Ikervis®

For treating dry eye disease that has not improved despite treatment with artificial tears in line with Shared Care Protocol. To be initiated by consultant ophthalmologists only. 

APCO July 2016.

13.05.03 Ciclosporin 

*Ciclosporin must be prescribed by BRAND NAME.*

In line with Shared Care Protocol for the treatment of:

    • Psoriasis plus other severe inflammatory skin disease
    • Atopic dermatitis

APCO May 2015.

09.05.01.02 Cinacalcet Mimpara®

For the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy as per NICE TA117.

Funded by specialised commissioning.

APCO January 2005.

04.06 Cinnarizine 

For vestibular disorders.

Available to purchase over the counter for motion sickness. 

05.01.12 Ciprofloxacin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.01.12 Ciprofloxacin 

Secondary care use only. 

APCO July 2010.

11.03.01 Ciprofloxacin 0.3%  

Suitable for prescribing in primary care following specialist recommendation.

12.01.01 Ciprofloxacin 2mg/ml Cetraxal®

Licensed ear drops now available. 

APCO July 2018. 

15.01.05 Cisatracurium Nimbex®

Specialist prescribing only.

04.03.03 Citalopram 

First choice antidepressant for the treatment of depression.

See Prescribing Guidelines for the Management of Moderate to Severe Depression.

Alternative SSRI for Generalised Anxiety Disorder when sertraline has been ineffective (second line). See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

08.01.03 Cladribine Mavenclad®

For treating relapsing–remitting multiple sclerosis as per NICE TA616.

Funded by specialised commissioning.

APCO March 2020.

 

05.01.05 Clarithromycin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO March 2014. 

05.01.05 Clarithromycin 

Secondary care use only. 

APCO July 2010.

05.01.06 Clindamycin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018.

07.02.02 Clindamycin 2% Dalacin®

For the treatment of bacterial vaginosis, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.01.06 Clindamycin 300mg/2mL Injection 

Secondary care use only. 

APCO July 2010.

A5.07.03 Clinipore® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

NB. 2.5cm x 5cm - to secure a bandage, not to be used directly on the skin. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

A5.02.08 Clinisorb  

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Please see OCCG Wound Management Formulary. NB. Can be cut to size of wound if needed.

APCO May 2015.

A2.02.02.02 Clinutren® Dessert 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

04.08.01 Clobazam 

Suitable for continuation in primary care following specialist initiation or recommendation.

Do not confuse with clonazepam.

13.04 Clobetasol propionate 0.05% Etrivex®

For moderate scalp psoriasis in line with Psoriasis pathway only. Second line for scalp. 

Very potent

APCO May 2018.

13.04 Clobetasol Propionate 0.05% Dermovate®

Available in cream, ointment and scalp application. 

Use in line with Guidelines for the use of Corticosteroids in Atopic Eczema.

Very potent

13.04 Clobetasone Butyrate 0.05% Eumovate®

Second-line treatment for moderate eczema (small quantities), in line with Guidelines for the use of Corticosteroids in Atopic Eczema..

Eumovate® cream is available to purchase over the counter, except where a larger quantity than 30g, in line with Clinical Commissioning Policy 88D.

Moderately potent

08.01.03 Clofarabine Evoltra®

For the treatment of relapsed/refractory acute lymphoblastic leukaemia.

05.01.10 Clofazimine 

Secondary care use only. 

APCO July 2010.

04.01.01 Clomethiazole Heminevrin®

Secondary care use only. 

06.05.01 Clomifene Citrate Clomid®

For anovulatory infertility and should only be prescribed by the treating consultant, in line with Clinical Commissioning Policy 11H.

GPs should not prescribe any fertility drugs.

04.03.01 Clomipramine 

Suitable for continuation in primary care following specialist initiation.

See Prescribing Guidelines for the Management of Moderate to Severe Depression.

04.03.01 Clomipramine Hydrochloride Anafranil® SR

Suitable for continuation in primary care following specialist initiation.

Standard release clomipramine is preferred to modified release clomipramine. In most patients the long half-life of clomipramine from the immediate release preparation is sufficient to allow once daily dosing (usually given at night).

04.02.03 Clonazepam 

Specialist initiation only for the initial management of agitated or disturbed behaviour associated with mania, but should not be used long-term.

Available orally only as a 500 microgram tablet and a 2mg tablet (IM injection no longer manufactured in the UK).

04.08.01 Clonazepam 

Suitable for continuation in primary care following specialist initiation or recommendation.

Do not confuse with clobazam.

04.08.02 Clonazepam 1mg/1mL 

Secondary care use only. 

02.05.02 Clonidine Catapres®
02.09 Clopidogrel 

Suitable for continuation in primary care following specialist initiation for prevention of occlusive vascular events as per NICE TA210.

APCO January 2011.

07.02.02 Clotrimazole 

For the treatment of vaginal candidiasis and trichomoniasis, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

13.10.02 Clotrimazole 1% 

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

See Guidelines for Antibiotic Prescribing in the Community 2018.

12.01.01 Clotrimazole 1% Solution Canesten®

Note this is called '1% solution' rather than 'ear drops'.

04.02.01 Clozapine 

In line with Shared Care Protocol for the treatment of:

    • Resistant schizophrenia (lack of satisfactory response) and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics
    • Resistant psychosis in Parkinson’s Disease.

See Treatment of psychosis and schizophrenia algorithm

APCO January 2011.

02.08.02 CoaguChek Testing Strips 

Restricted to patients who meet the following criteria:

  • To be on long-term oral anticoagulation.
  • To have sufficient eye sight to enable them to use the coagulometer.
  • To be sufficiently dextrous to carry out self-testing. (Training may be considered for patient carers or next of kin who meet the eye sight and dexterity criteria.)
  • To have GP support for the prescribing of strips.
  • To already be dosed by the Oxfordshire Anticoagulation Service (JR, Churchill or Horton hospitals).
  • To be able to afford the coagulometer (about £500 for the CoaguCheks and approximately £20 for enough quality control solutions for approximately one year, not including the training programme).

The patient would have to receive suitable training to carry out self-testing and this would normally be provided by the hospital anticoagulation service if self-testing is agreed appropriate.

 

APCO September 2018. 

13.09 Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1®

Available to purchase over the counter for treatments of seborrheic dermatitis or psoriasis in line with Clinical Commissioning Policy 88D.

13.05.02 Coal tar lotion 5% Exorex®

For the treatment of psoriasis of the skin and scalp in line with NICE guidance.

Available to purchase over the counter. 

02.02.04 Co-amilofruse Furosemide and amiloride
05.01.01.03 Co-Amoxiclav 

Secondary care use only. 

APCO July 2010.

05.01.01.03 Co-Amoxiclav 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

04.09.01 Co-Beneldopa Madopar® CR

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease.

Suitable for continuation in primary care.

04.09.01 Co-Beneldopa Madopar®

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease. 

Suitable for continuation in primary care.

04.09.01 Co-Careldopa Sinemet® CR

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease.

Suitable for continuation in primary care.

04.09.01 Co-Careldopa Sinemet®

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease.

Suitable for continuation in primary care.

04.09.01 Co-Careldopa Half Sinemet® CR

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease.

Suitable for continuation in primary care.

13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 Dianette®

MHRA advice:
The benefits of co-cyprindiol outweigh the risks in women of reproductive age for the treatment of skin conditions related to androgen sensitivity (eg. severe acne withor without seborrhoea) and hirsutism:

  • Co-cyprindiol provides effective contraception in these women. An additional hormonal contraceptive should not be used in combination with co-cyprindiol. 
  • The need to continue treatment should be evaluated periodically by the treating physician.
  • The risk of VTE is rare but this remains an important side effect, and healthcare professionals should themselves be vigilant for signs and counsel patients to remain vigilant for signs and symptoms.


CSM Advice: Co-cyprindiol is licensed for use in women with severe acne which has not responded to oral antibacterials and for moderately severe hirsutism; it should not be used solely for contraception. It is contra-indicated in those with a personal or close family history of venous thromboembolism. Women with severe acne or hirsutism may have an inherently increased risk of cardiovascular disease.

01.06.02 Co-danthrusate 

For constipation in terminally ill patients.

01.04.02 Codeine 

Tablets 15mg, 30mg, Syrup (25mg/5mL).

04.07.02 Codeine 

In line with Opioid Prescribing Guidelines for Non Cancer Pain.

APCO September 2015. 

10.01.04 Colchicine 
09.06.04 Colecalciferol 1000 unit capsules/ tablets Fultium-D3®, Desunin®

Available to purchase over the counter so only prescribe in patients with established osteopenia or osteoporosis or on advice of renal unit, in line with Clinical Commissioning Policy 88D. 

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol 2,740units/ml drops Fultium-D3® Drops

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

NB. 3 drops contain 200 units.

09.06.04 Colecalciferol 20,000 unit capsules Plenachol®, Aviticol®, Fultium-D3®

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol 2000 units/ml drops SunVit-D3® Drops

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

NB. 1 drop contain 100 units. 

09.06.04 Colecalciferol 25,000 unit liquid Invita D3®

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol 3200 unit capsules Fultium-D3®

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol 40,000 unit capsules Plenachol®

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol 800 unit capsules/ tablets Invita D3®, Fultium-D3®, Desunin®

Invita D3® is more cost-effective than Fultium D3® and Desunin®.

Available to purchase over the counter so only prescribe in patients with established osteopenia or osteoporosis or on advice of renal unit, in line with Clinical Commissioning Policy 88D. 

For vitamin D deficiency in line with Pathway for Treating Vitamin D Deficiency in Adults (APCO September 2016). 

Also see Vitamin D Supplementation in Pregnancy Guidelines and Vitamin D Supplementation in Pregnancy Algorithm (APCO September 2017).

09.06.04 Colecalciferol and Calcium Carbonate Calci-D®

Calci-D is the most cost-effective calcium and vitamin D preparation. See Prescribing Points Dec 2016.

Available as a chewable tablet (1 tablet daily).

09.06.04 Colecalciferol and Calcium Carbonate Calceos® Chewable tablets.
09.06.04 Colecalciferol and Calcium Carbonate Natecal D3®

Chewable tablets.

09.06.04 Colecalciferol and Calcium Carbonate Adcal-D3®

Chewable tablets.

09.06.04 Colecalciferol and Calcium Carbonate Adacl D3®
09.06.04 Colecalciferol and Calcium Carbonate Accrete-D3®
09.06.04 Colecalciferol and Calcium Carbonate Adacl D3® Caplets
09.06.04 Colecalciferol and Calcium Carbonate Calcichew D3® Forte

Chewable tablets.

02.12 Colesevelam Cholestagel®

Please note - due to a current manufacturing issue with colestyramine it has been agreed that clinicians can prescribe colesevelam on a temporary basis without having to seek prior approval via the OUH. Please ensure this is added to the Acute medication only to ensure it is switched back as soon as the stock issue is resolved

24th May 2019

Suitable for prescribing in primary care following recommendation from gastroenterology only (for bile acid malabsorption in patients with a true intolerance to colestyramine and colestipol). Gastroenterology will have to obtain ‘Prior Approval’ from the Medicines Optimisation team.

GPs will be notified by Medicines Optimisation team if approved for use in individual patients.

APCO September 2016.

02.12 Colestipol Colestid®

See Lipid Modification Guidance. A bile acid sequestrant may be used for particular patients groups after secondary care advice oxon.diabetes_lipidsadvice@nhs.net.

01.09.02 Colestyramine 

Powder, sugared and sugar free options

02.12 Colestyramine 

See Lipid Modification Guidance. A bile acid sequestrant may be used for particular patients groups after secondary care advice oxon.diabetes_lipidsadvice@nhs.net.

05.01.07 Colistimethate Sodium 

Amber Traffic Light  For the treatment of Pseudomonas aeruginosa (PsA) colonised non-cystic fibrosis bronchiectasis. Colomycin is the product of choice. See OUH patient leaflet here

Red Traffic Light  For pseudomonas lung infection in cystic fibrosis as per NICE TA276. Funded by specialised commissioning (APCO May 2013).

13.10.05 Collodion Flexible BP 

Flexible collodion may be used to seal minor cuts and wounds that have partially healed.

01.01.01 Co-magaldrox Maalox®

Available to purchase over the counter. 

Anyone requiring more than occassionally is likely to be more suitable for a PPI or equivalent, in line with Clinical Commissioning Policy 88D. 

06.04.01.01 Combined continuous HRT patch Evorel® Conti

First line transdermal option for combined continuous HRT treatment, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

06.04.01.01 Combined continuous HRT tablet Kliovance®

First line oral combined continuous HRT treatment, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

06.04.01.01 Combined cyclical HRT patch FemSeven® Sequi

Alternative option if skin allergy or poor absorption with Evorel® Sequi, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

06.04.01.01 Combined cyclical HRT patch Evorel® Sequi

First line transdermal sequential/ cyclical combined HRT option, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

06.04.01.01 Combined cyclical HRT tablet Femoston®, Prempak-C®

In line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

NB. Prempak-C has been discontinued.

06.04.01.01 Combined cyclical HRT tablet Elleste-Duet®

First line treatment option for sequential/ cyclical combined HRT treatment, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

07.03.01 Combined Hormonal Contraceptives Logynon ED®

Phasic standard strength (28-day ‘Every day’ preparation).

07.03.01 Combined Hormonal Contraceptives Evra

Evra® patches should be restricted for use in women who are likely to comply poorly with combined oral contraceptives. 

 The Scottish Medicines Consortium (September 2003).

07.03.01 Combined Hormonal Contraceptives Synphase®

Phasic standard strength (21 day preparation).

07.03.01 Combined Hormonal Contraceptives NuvaRing®

Second or third line option contraceptive when other methods have proved unacceptable.

APCO July 2009.

A5.08.03 Comfigrip® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

NB. Size D, E, F and G - all 1 meter lengths. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

A5.08.03 Comfinette® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

NB. Size 56 and 78 used as a liner under sub bandage wool if the patient has eczema or irritant dermatitis or a known sensitivity to wool. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

A2.02.02.03 Complan® Shake 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.01.02 Complan® Shake  

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

09.02.02.01 Compound Sodium Lactate Intravenous Infusion 

Secondary care use only. 

A5.09 Compression Hosiery  

Green Traffic Light  For prevention of recurrence of leg ulcers and can be used for 3 months for varicose veins. Activa® is the stocking of choice. Also see Clinical Commissioning Policy 1D on lnterventional Procedures for Varicose Veins.

Black Traffic Light  No evidence of benefit for DVT and early use in oedema to prevent lymphodema.

APCO September 2015. 

03.04.03 Conestat Alfa Ruconest®

Specialist prescribing only for angioedema. Funded by specialised commissioning.

APCO March 2020.

06.04.01.01 Continuous combined HRT patch FemSeven® Conti

Alternative option if skin allergy or poor absorption with Evorel®, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

06.04.01.01 Continuous combined HRT tablet Indivina®,Angeliq®, Femoston® Conti, Premique® low dose

In line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

NB. Stock supply issues with Premique® Low Dose 0.3mg/1.5mg have been resolved. Premique® 0.625mg/5mg have been discontinued.

01.04.02 Co-Phenotrope Lomotil®

Contains diphenoxylate (opioid) and atropine. Available for patients in whom loperamide and codeine have failed, but causes anticholinergic side effects.

Can be sold to the public for adults and children over 16 years (provided packs do not contain more than 20 tablets) as an adjunct to rehydration in acute diarrhoea (max. daily dose 10 tablets).

05.01.08 Co-trimoxazole 

Secondary care use only. 

APCO July 2010.

05.01.08 Co-trimoxazole 

For continuation following recommendation from specialist.

APCO July 2010.

A2.03.01 Cow and Gate Pepti-Junior® 

Suitable when cow's milk protein allergy is also accompanied by malabsorption.

Suitable for continuation in primary care following initiation or recommendation from a specialist or dietitian only, in line with:


Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

APCO September 2017.

08.01.05 Crisantaspase Erwinase®

For patients being treated on the UKALL 2011 (Paediatric Haemato-oncology).

 

08.01.05 Crizotinib Xalkori®

For:

  • Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA406 (APCO November 2016).
  • Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA422 (APCO January 2017).
  • For treating ROS1-positive advanced non-small-cell lung cancer as per NICE TA529 (APCO September 2018). 

Funded by specialised commissioning.

13.03 Crotamiton 10% Eurax®

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

A5.03.04 Cutimed® Sorbact 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Please see OCCG Wound Management Formulary.

APCO May 2015.

04.06 Cyclizine 

Available to purchase from pharmacies. 

11.05 Cyclopentolate Eye drops 

Suitable for prescribing in primary care following specialist recommendation.

Available as 0.5% or 1% eye drops.

11.05 Cyclopentolate Hydrochloride single use Minims® Cyclopentolate Hydrochloride

Suitable for prescribing in primary care following specialist recommendation.

Available as 0.5% and 1%.

08.01.01 Cyclophosphamide 

Secondary care use only. 

APCO July 2008.

05.01.09 Cycloserine 

Secondary care use only. 

APCO July 2010.

03.04.01 Cyproheptadine Periactin®

For use as part of paediatric oncology anti-emetic policy.

08.03.04.02 Cyproterone 

Suitable for continuation in primary care following initiation in secondary care by urology or oncology.

06.04.02 Cyproterone Acetate 

Suitable for continuation in primary care following specialist initiation.

08.01.03 Cytarabine 

Secondary care use only. 

02.08.02 Dabigatran Pradaxa®

Green Traffic Light  For preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. See Primary Care Prescriber Decision Support for DOACs in Atrial Fibrillation.

APCO January 2017.

Amber Traffic Light  For treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.

APCO May 2015.

Red Traffic Light  For preventing VTE after total hip or knee replacement in adults in line with NICE TA157. 

APCO November 2008.

NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.

08.01.05 Dabrafenib Tafinlar®

Red 

  • In combination with trametinib for treating unresectable or metastatic melanoma as per NICE TA396 (APCO July 2016).
  • In combination with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544 (APCO November 2018).

Funded by specialised commissioning.

 Black Traffic Light Not recommended for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer in combination with trametinib as per NICE TA564 (terminated appraisal).

APCO March 2019.

08.01.05 Dacarbazine 

Secondary care use only. 

05.03.03.02 Daclatasvir  Daklinza®

For the treatment of hepatitis C as per NICE TA364 and NHSE B07/P/a policy.

Funded by specialised commissioning.

APCO January 2016.

08.02.04 Daclizumab Zinbryta®

For treating relapsing-remitting multiple sclerosis as per NICE TA441. Funded by specialised commissioning. 

APCO July 2017. 

08.01.05 Dacomitinib  Vizimpro®

For untreated EGFR mutation-positive non-small-cell lung cancer as per NICE TA595.

Funded by specialised commissioning. 

APCO September 2019.

08.01.02 Dactinomycin Actinomycin D

Secondary care use only. 

APCO July 2008.

02.08.01 Dalteparin Fragmin®

In line with Dalteparin Guideline and Shared Care Protocol for Primary Care:

Amber Traffic Light  For sub-therapeutic INRs, DVT in patients with cancer, IV drug users & first doses in high risk of VTE in pregnancy.

Red Traffic Light  For perioperative anticoagulation, extended thromboprophylaxis & post-partum, trauma and intermediate risk of VTE in pregnancy.

Brown Traffic Light  For DVT & long haul flight prophylaxis.

APCO September 2016.

Brown Traffic Light For DVT (out of hours), in line with DVT service specification. Prescribe one off initial dose only if presentation of DVT outside of DVT clinic hours.

APCO September 2018.

Red Traffic Light For venous thromboprophylaxis for lower limb immobilisation. 

APCO July 2017.

NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.

02.08.01 Danaparoid Orgaran®

Secondary care use only. 

10.02.02 Dantrolene  Dantrium®
15.01.08 Dantrolene Sodium Dantrium Intravenous®

Secondary care use only. 

06.01.02.03 Dapagliflozin Forxiga▼®

Green 1st line SGLT2i option for type 2 diabetes (empagliflozin also first line).

Dapagliflozin has shown CV outcome benefit in primary prevention; empagliflozin, in secondary prevention.

See SGLT2i checklist, patient information leaflet on DKA risk, and OCCG letter to clinicians.

APCO May 2019.

Amber Traffic Light In combination with insulin for treating type 1 diabetes as per NICE TA597. 

APCO November 2019.

06.01.02.03 Dapagliflozin and Metformin Xigduo®

1st line SGLT2i option for type 2 diabetes (empagliflozin also first line).

Dapagliflozin has shown CV outcome benefit in primary prevention; empagliflozin, in secondary prevention.

See SGLT2i checklist, patient information leaflet on DKA risk, and OCCG letter to clinicians.

APCO May 2019.

05.01.10 Dapsone 

Secondary care use only. 

APCO July 2010.

05.01.07 Daptomycin Cubicin®

For use at the NOC only on advice of ID or Microbiology Consultants in specific situations.

APCO January 2011.

08.01.05 Daratumumab Darzalex®

Red Traffic Light  

  • Monotherapy for treating relapsed and refractory multiple myeloma as per NICE TA510 (APCO May 2018). 
  • With bortezomib and dexamethasone for previously treated multiple myeloma as per NICE TA573 (APCO May 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for treating relapsed or refractory multiple myeloma with lenalidomide and dexamethasone.

APCO September 2017.

09.01.03 Darbepoetin alfa Aranesp®

For use by Haematology only for symptomatic anaemia associated with CRF or chemotherapy.

Funded by specialised commissioning.

APCO November 2005.

05.03.01 Darunavir Prezista®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

APCO September 2005.

05.03.03.02 Dasabuvir Exviera®

In combination with ombitasvir-paritaprevir-ritonavir for treating chronic hepatitis C as per NICE TA365.

Funded by specialised commissioning.

APCO January 2016.

08.01.05 Dasatinib Sprycel®

Red Traffic Light  For the treatment of:

  • Imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.
  • Untreated chronic myeloid leukaemia as per NICE TA426.

Funded by specialised commissioning.

APCO January 2017.

Black Traffic Light  Not recommended for patients with CML resistant to standard dose imatinib or unable to tolerate imatinib as per NICE TA241.

APCO March 2012.

08.01.02 Daunorubicin 

Secondary care use only. 

A5.07 DebriSoft® 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

APCO May 2015.

09.01.03 Deferasirox Exjade®
  • For the treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias as per NHSE Policy 16070/P. Funded by specialised commissioning (APCO November 2009).
  • Approved at MMTC as 2nd line in myelodysplastic syndromes (MDS). In line with TVPC policy on Iron Chelating Drugs in MDS (APCO May 2019).

 

09.01.03 Deferiprone Ferriprox®

For use by Haematology only.

Funded by specialised commissioning.

APCO March 2006.

08.03.04.02 Degarelix Firmagon®

For treating newly diagnosed advanced hormone-dependent prostate cancer with spine metastases as per NICE TA404.

APCO July 2017.

05.01.09 Delamanid Deltyba®

Secondary care use only. 

05.01.03 Demeclocycline Hydrochloride  

Suitable for prescribing in primary care following specialist recommendation for the treatment of chronic hyponatraemia associated with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).

NB. Not routinely used as an antibiotic, please contact microbiology for advice.

06.06.02 Denosumab XGEVA®

Red Traffic Light Secondary care use only

  • For the prevention of skeletal-related events in adults with bone metastases from solid tumours as per NICE TA265 (APCO November 2012).
  • For tumor induced hypercalcemia. Agreed at MMTC Oct 2019. (APCO November 2019).

Black Traffic Light  Not recommended for

  • preventing complications that result from prostate cancer spreading to the bone as per NICE TA265 (APCO November 2012).
  • preventing skeletal-related events in multiple myeloma as per NICE TA549 (APCO January 2019).
06.06.02 Denosumab Prolia®

Brown Traffic Light  Third line treatment for primary and secondary prevention of osteoporotic fractures in line with Denosumab for Osteoporosis in Primary Care Guidelines.

APCO May 2018. 

Black Traffic Light  For treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. NB. This is under review.

APCO September 2010. 

13.02.01 Dermol® cream 

See Emollient Prescribing Guidelines.

    • Reserve for where there is a concern about Staph colonisation.
    • Intermittent use can reduce frequency of infection related flares of atopic eczema.
    • This should be targeted and short term use only.

APCO March 2020.

09.01.03 Desferrioxamine Mesilate Desferal®

Secondary care use only for iron overload.

Funded by specialised commissioning.

APCO March 2006.

15.01.02 Desflurane Suprane®

Specialist prescribing only.

06.05.02 Desmopressin 

Amber Traffic Light  For diabetes insipidus. 

Green Traffic Light  For nocturnal enuresis (oral preparation).

06.05.02 Desmopressin Octim®

Secondary care use only for nocturnal enuresis.

APCO September 2005.

07.03.02.01 Desogestrel 

Prescribe generically.

Cerazette is 3.5 times more expensive than generic. 

APCO April 2020.

06.03.02 Dexamethasone 
10.01.02.02 Dexamethasone 
11.04.01 Dexamethasone 0.1% 

Suitable for prescribing in primary care following specialist recommendation.

11.04.01 Dexamethasone 0.1% Eye drops Maxidex®

Suitable for prescribing in primary care following specialist recommendation.

11.04.01 Dexamethasone Intracameral injection 

Secondary care use only by glaucoma surgeons for galucoma surgery with laser.

APCO November 2018.

11.04.01 Dexamethasone Intravitreal Implant Ozurdex®

For the treatment of:

  • Macular oedema secondary to retinal vein occlusion as per NICE TA229 (APCO September 2015).
  • Diabetic macular oedema as per NICE TA349 (APCO September 2015). Also see Clinical Commissioning Policy 249B.
  • Non-infectious uveitis as per NICE TA460 (APCO September 2017).


Prior notification required.

11.04.01 Dexamethasone with Antibacterials  Maxitrol®

Suitable for prescribing in primary care following specialist recommendation.

Contains dexamethasone 0.1%, neomycin sulfate 3500 units /g and polymyxin B sulfate 6000 units/mL.

12.01.01 Dexamethasone with Antibacterials Otomize®

Ear spray - (Dexamethasone 0.1%, Neomycin Sulphate 3250 units per mL and Glacial Acetic Acid 2%).

12.01.01 Dexamethasone with Antibacterials Sofradex®

Contains dexamethasone 0.05%, Framycetin Sulphate 0.5%, Gramicidin 0.005%.

11.04.01 Dexamethasone with Antibacterials (Eye) Sofradex®

Suitable for prescribing in primary care following specialist recommendation.

Contains dexamethasone (as sodium metasulphobenzoate) 0.05%, framycetin sulfate 0.5% and gramicidin 0.005%.

04.04 Dexamfetamine 

For Attention Deficit Hyperactivity Disorder (ADHD) in line with Shared Care Protocol.

*Please note that adult patients will be discharged to primary care once stable as per Shared Care Protocol.

Also see:

APCO January 2018.

15.01.04.04 Dexmedetomidine  Dexdor®

Secondary care use only for sedation of mechanically ventilated adult patients in critical care. Approved at MMTC.

APCO May 2019.

08.01 Dexrazoxane Savene®

Secondary care use only for anthracycline extravasation. 

APCO July 2018. 

09.02.02.02 Dextran 40® 

Restricted to post pancreas transplant patients only. 

Secondary care use only. 

04.07.02 Diamorphine 

Secondary care use only. 

APCO July 2011.

04.07.02 Diamorphine 

Green Traffic Light  For acute or severe pain.

Red Traffic Light  For substance misuse.

APCO July 2011.

04.01.02 Diazepam 
04.08.02 Diazepam 

Secondary care use only.

10.02.02 Diazepam 
15.01.04.01 Diazepam 
04.08.02 Diazepam Rectal Tubes 

10mg tube can be prescribed in palliative care. 

16.01 Dibotermin alfa InductOs®

For primary and revision spinal fusion.

Funded by specialised commissioning.

APCO May 2018.

04.07.04.01 Diclofenac 

For treatment of acute migraine, see Migraine: Acute Therapy Guidelines (Adult)

APCO November 2016. 

11.08.02 Diclofenac Voltarol® Ophtha Multidose

Restricted for patients requiring a preservative free NSAID eye drop. Suitable for prescribing in primary care following specialist recommendation.

For all other patients recommend changing to Ketorolac eye drops.

10.01.01 Diclofenac Sodium 

MHRA 2013: Diclofenac is contraindicated in patients with established:

  • Ischaemic heart disease
  • Peripheral arterial disease
  • Cerebrovascular disease
  • Congestive heart failure (New York Heart Association [NYHA] classification II–IV)

10.03.02 Diclofenac Gel 

Available to purchase over the counter for short-term use.

Only prescribe if required for a chronic condition that is not expected to improve and where patient is not suitable for oral NSAIDs, in line with Clinical Commissioning Policy 88D

05.03.01 Didanosine Videx®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

08.03.01 Diethylstilbestrol 

Suitable for continuation in primary care following specialist initiation.

13.04 Diflucortolone Valerate 0.1% Nerisone®

Potent

13.04 Diflucortolone Valerate 0.3% Nerisone Forte®

Very potent

02.01.01 Digoxin 

For heart failure, see The Management of Heart Failure in Primary Care. 

02.01.01 Digoxin specific antibody fragments Digifab®

Secondary care use only. 

04.07.02 Dihydrocodeine 

NB: Not included in Opioid Prescribing Guidelines for Non Cancer Pain.

05.04.02 Diloxanide 

Secondary care use only. 

APCO July 2010.

01.07.04 Diltiazem 2%  Anoheal®

For chronic anal fissure, second line to GTN for use by secondary care only.

APCO January 2019.

02.06.02 Diltiazem Hydrochloride 
08.02.04 Dimethyl fumarate Tecfidera®

For the treatment of relapsing-remitting multiple sclerosis, as per NICE TA320 and in line with Monitoring Protocol 

APCO July 2016.

Funded by specialised commissioning. 

13.05.03 Dimethyl fumarate Skilarence®

For treating moderate to severe plaque psoriasis, as per NICE TA475

APCO November 2017. 

07.04.04 Dimethyl Sulphoxide Bladder Instillation 50% 

Secondary care use only for symptomatic relief in patients with interstitial cystitis (Hunner's ulcer).

07.01.01 Dinoprostone Prostin E2®

Secondary care use only. 

Note: Prostin E2 Vaginal Gel and Vaginal Tablets are not bioequivalent.

08.02.04 Dinutuximab Beta Qarziba®

For treating neuroblastoma as per NICE TA538.

Funded by specialised commissioning.

APCO November 2018.

02.09 Dipyridamole MR 

Suitable for continuation in primary care following specialist initiation for prevention of occlusive vascular events as per NICE TA210.

APCO January 2011.

11.99.99.99 Disodium Edetate 0.37%  

For secondary care (ophthalmology) use only.

02.03.02 Disopyramide 

Suitable for continuation in primary care following initiation by a cardiologist.

04.10.01 Disulfiram Antabuse®

Suitable for continuation in primary care following recommendation by specialist service (Turning Point)

13.05.02 Dithranol cream Dithrocream®

Creams 0.1%, 0.25%, 0.5%, 1% and 2%.

Dithranol should not be used in people with acute or pustular psoriasis or inflamed psoriasis. Avoid using dithranol on the face.

Prescription only medicine if dithranol content more than 1%, otherwise may be sold to the public. 

13.05.02 Dithranol Paste BP 

Dithranol in zinc and salicylic acid (Lassar's) paste. Usual strengths 0.1–1% of dithranol. Restricted to dermatology use only. 

02.07.01 Dobutamine 

Specialist prescribing only.

01.06.02 Docusate Sodium Diotyl®, Docusol®

  • Diotyl® capsule
  • Docusol® solution (Utterly unpalatable - only fit for use down tubes.

05.03.01 Dolutegravir Tivicay®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

05.03.01 Dolutegravir, abacavir & lamivudine Triumeq®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

04.06 Domperidone 

Brown Traffic Light  For short term use for nausea and vomiting only as per MHRA advice.

Domperidone is now contraindicated in people:

    • With conditions where cardiac conduction is, or could be, impaired
    • With underlying cardiac diseases such as congestive heart failure
    • Receiving other medications known to prolong QT interval or potent CYP3A4 inhibitors
    • With severe hepatic impairment

APCO July 2014.

Black Traffic Light  For use with enteral feeds as per NICE ESUOM18.

APCO January 2014.

04.11 Donepezil hydrochloride  

For the treatment of Alzheimer's disease following recommendation by specialist or clinician with specialist expertise, except for practices signed up to Primary Care Memory Assessment Service (PCMAS) who may initiate treatment.

See Dementia Prescribing Guidelines and Clinical Commissioning Policy 134B

APCO September 2018.

02.07.01 Dopamine Hydrochloride 

Specialist prescribing only.

02.07.01 Dopexamine Dopacard®

Specialist prescribing only.

 

03.07 Dornase Alfa Pulmozyme®

Specialist prescribing only.

Funded by specialised commissioning.

11.06 Dorzolamide 20mg/ml plus timolol 5mg/ml Eylamdo®

Suitable for prescribing in primary care following specialist recommendation.

For patients intolerant or who have allergies to the preservative containing preparations only in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

NB. This is much cheaper than the unit dose option (Cosopt®) i.e. £14.29/month compared to £20.54.

APCO March 2018.

11.06 Dorzolamide 2% Trusopt®

Suitable for prescribing in primary care following specialist recommendation.

For patients intolerant or who have allergies to the preservative containing preparations only in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

NB: Eydelto® Preservative free multidose is much cheaper than Trusopt® unit dose i.e. £12.09/month compared to £24.18.  

APCO March 2018.

11.06 Dorzolamide 20mg/ml 0.2ml Eydelto®

Suitable for prescribing in primary care following specialist recommendation.

For patients intolerant or who have allergies to the preservative containing preparations only in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

NB. This is much cheaper than the unit dose option (Trusopt®) i.e. £12.09/month compared to £24.18.

APCO March 2018.

11.06 Dorzolomide 2% with Timolol 0.5% Cosopt®

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

NB: Eylamdo® preservative free multidose is much cheaper than Cosopt® unit dose i.e. £14.29/month compared to £20.54.

APCO March 2018.

11.06 Dorzolomide 2% Eye drops 

Suitable for prescribing in primary care following specialist recommendation.

In line with Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

03.05.01 Doxapram Dopram®

Secondary care use only. 

15.01.07 Doxapram Dopram®

Specialist prescribing only.

02.05.04 Doxazosin 
08.01.02 Doxorubicin Caelyx®

For the treatment of:

  • Recurrent ovarian cancer as per NICE TA389 (APCO May 2016).
  • Advanced soft tissue sarcoma in combination with doxorubicin as per NICE TA465 (APCO September 2017).

05.01.03 Doxycycline 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

13.06.02 Doxycycline 

Second line treatment for moderate acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

02.03.02 Dronedarone Multaq®

For the treatment and management of non permanent atrial fibrillation in line with Shared Care Protocol and NICE TA197.

APCO January 2011.

04.06 Droperidol Xomolix®

Secondary care use only for prevention and treatment of postoperative nausea and vomiting.

06.01.02.03 Dulaglutide Trulicity®

First line option in line with updated GLP-1 receptor agonist guidelines (previously for those who would gain benefit from once weekly and can’t have semaglutide).

See patient agreement form.

APCO September 2019.

04.03.04 Duloxetine 

Green Traffic Light  Alternative first line options when an SSRI is contraindicated for Generalised Anxiety Disorder. See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017.

Amber Traffic Light  Suitable for prescribing in primary care following specialist recommendation. See Prescribing Guidelines for the Management of Moderate to Severe Depression.

APCO March 2005.

04.07.03 Duloxetine 

For painful diabetic neuropathy in line with Guidelines for the Management of Neuropathic Pain in Primary Care.

Discontinue if inadequate response after trial period, review treatment  at least every 3 months.

APCO March 2017.

07.04.02 Duloxetine 

For stress incontinence following recommendation from specialists only.

Duloxetine should not be prescribed for overactive bladder.

APCO July 2006.

13.05.03 Dupilumab Dupixent®
  • For Eosinophilic asthma - FOC medicine following trial use in small group of patients (APCO September 2018).
  • For treating moderate to severe atopic dermatitis as per NICE TA534 (APCO May 2019).

 

08.01 Durvalumab Imfinzi®

For treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in line with NICE TA578.

Funded by specialised commissioning.

APCO July 2019.

13.09 E45® Dry Scalp Shampoo 

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D. No prescribing except where required for a chronic skin condition or for skin care in the elderly who would otherwise be at risk of skin breakdown.

APCO September 2018.

A5.08.02 Easifix K® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015.

09.01.03 Eculizumab Soliris®

For atypical haemolytic uraemic syndrome.

Funded by specialised commissioning.

02.08.02 Edoxaban Lixiana®

Green Traffic Light  For preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. See Primary Care Prescriber Decision Support for DOACs in Atrial Fibrillation.

APCO January 2017.

Amber Traffic Light  For treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.

APCO January 2017.

NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.

05.03.01 Efavirenz Sustiva®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

05.03.03.02 Elbasvir and Grazoprevir Zepatier®

For treating chronic hepatitis C as per NICE TA413.

Funded by specialised commissioning.

APCO November 2016.

04.07.04.01 Eletriptan Relpax®

For treatment of acute migraine if unaccetable side effects with first-line triptans and for recurrent migraine, in line with Migraine: Acute Therapy Guidelines (Adult)

APCO November 2016. 

09.01.04 Eltrombopag Revolade®

Red Traffic Light  For treating chronic immune (idiopathic) thrombocytopenic purpura as per NICE TA293.

Prior approval required.

APCO September 2013. 

Black Traffic Light  Severe aplastic anaemia refractory to immunosuppressive therapy (NICE TA382 - terminated appraisal).

APCO March 2016.

01.04.02 Eluxadoline Truberzi®

Suitable for continuation in primary care following specialist initiation for treating irritable bowel syndrome with diarrhoea as per NICE TA471. 

APCO November 2017.

05.03.01 Elvitegravir, Cobicistat, Emtricitabine and Tenofovir alafenamide fumarate Genvoya®

Secondary care prescribing only.

Funded by specialised commissioning. 

APCO May 2017. 

11.04.02 Emedastine Emadine®

For use as a second line agent in patients sensitive to or not responding to cromoglycate.

NB. Discontinued.

02.11 Emicizumab 

Secondary care use only (haemophilia).

APCO September 2018.

 

13.02.01 Emollient preparation containing Urea Balneum® cream

See Emollient Prescribing Guidelines.

For severe dry skin (e.g. ichthyosis). Contains ceramide which is a lipid lamella mimicking agent resulting in transepidermal water loss of 24hrs.

APCO March 2020.

13.02.01 Emollin® spray 

See Emollient Prescribing Guidelines.

Only for difficult to reach areas or patients unable to use alternative preparations as this is not the most cost effective preparation.

Covers three times the skin area as equivalent volume of cream/ointment. 

APCO March 2020.

06.01.02.03 Empagliflozin Jardiance▼®

1st line SGLT2i option for type 2 diabetes (dapagliflozin also first line)

Dapagliflozin has shown CV outcome benefit in primary prevention; empagliflozin, in secondary prevention

See SGLT2i checklistpatient information leaflet on DKA risk and OCCG letter to clinicians.

APCO November 2018.

06.01.02.03 Empagliflozin and Metformin Synjardy®

1st line SGLT2i option for type 2 diabetes (dapagliflozin also first line)

Dapagliflozin has shown CV outcome benefit in primary prevention; empagliflozin, in secondary prevention

See SGLT2i checklistpatient information leaflet on DKA risk and OCCG letter to clinicians.

APCO November 2018.

05.03.01 Emtricitabine Emtriva®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

05.03.01 Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

APCO September 2005.

02.05.05.01 Enalapril Maleate 

Restricted to existing patients. Not to be initiated in new patients.

APCO November 2005.

08.01.05 Encorafenib Braftovi®

For treating unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with binimetinib as per NICE TA562.

Funded by specialised commissioning.

APCO March 2019.

 

05.03.01 Enfuvirtide Fuzeon®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

APCO September 2005.

A2.02.02.01 Ensure Plus Savoury 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Ensure® Compact 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Ensure® Plus Commence 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.02 Ensure® Plus Creme 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.01.02 Ensure® Plus Juce 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Ensure® Plus Milkshake style 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.03 Ensure® Twocal 

Brown Traffic Light  Restricted for use only where a patient is under a specialist/dietitian. 2kcal/ml supplements can be used to reduce the volume in bolus feeding via PEG tube or in fluid restricted patients, such as ascites in liver disease. See Clinical Commissioning Policy 277

APCO July 2014.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Ensure® Plus Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Ensure® Plus Yoghurt style 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.01.02 Ensure® Shake 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

04.09.01 Entacapone Comtess®

Must be initiated and monitored by specialists in secondary care with expertise in management of patients with Parkinson's disease.

APCO September 2006.

05.03.03.01 Entecavir Baraclude®

Use by Consultant Hepatologist for oral Hepatitis B treatment only.

Funded by specialised commissioning.

APCO September 2008.

08.03.04.02 Enzalutamide Xtandi®

Red Traffic Light For the treatment of:

  • Metastatic hormone-relapsed prostate cancer previously treated with a docetaxel containing regimen as per NICE TA316.
  • Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated as per NICE TA377.

APCO March 2016.

Black Traffic Light Not recommended for hormone-relapsed non-metastatic prostate cancer as per NICE TA580.

APCO July 2019. 

02.07.02 Ephedrine 

Specialist prescribing only.

12.02.02 Ephedrine 

Nasal drops 0.5%
Nasal drops 1%

13.02.01 Epimax ® ExCetra Cream 

See Emollient Prescribing Guidelines.

Equivalent to Cetraben®.

APCO March 2020.

13.02.01 Epimax ® Paraffin-Free ointment 

See Emollient Prescribing Guidelines.

May be suitable where flammability is an issue.

APCO March 2020. 

13.02.01 Epimax® Isomol gel 

See Emollient Prescribing Guidelines.

Cost effective alternative to Aproderm®, Doublebase® & Zerodouble®

Available as a squeeze bottle (flexi-dispenser) which may be difficult for patients with dexterity problems.

APCO March 2020.

13.02.01 Epimax® Oatmeal Cream 

See Emollient Prescribing Guidelines

Colloidal oatmeal containing emollients are borderline substances & may only be prescribed in accordance with the advice of the Advisory Committee on Borderline Substances (ACBS) for the clinical conditions listed (see current BNF).

They may be considered for children who are sensitive to other emollients but should not be used routinely.

APCO March 2020.

13.02.01 Epimax® ointment 

See Emollient Prescribing Guidelines.

Alternative to Epaderm® (manufacturing process produces a creamier texture) More cost-effective than Hydromol® and Zeroderm® (WSP).

APCO March 2020

13.02.01 Epimax® Original cream 

See Emollient Prescribing Guidelines.

Mimics Diprobase. Available as a squeeze bottle (flexi-dispenser), which may be difficult for patient with dexterity problems. Suitable as a soap substitute.

APCO March 2020.

08.01.02 Epirubicin 

Secondary care use only. 

02.02.03 Eplerenone 
  • Second line for patients that cannot tolerate spironolactone (APCO November 2013).
  • First line mineralocorticoid receptor antagonist for young (<65) male patients, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction and clinical evidence of heart failure after recent MI (APCO November 2017). 
09.01.03 Epoetin alfa Eprex®

Secondary care use only. 

Funded by specialised commissioning.

APCO November 2005.

09.01.03 Epoetin beta NeoRecormon®

Secondary care use only. 

Funded by specialised commissioning.

APCO November 2005.

02.08.01 Epoprostenol Flolan®

Specialist prescribing only.

Funded by specialised commissioning.

09.06.04 Ergocalciferol 

Secondary care use only. 

07.01.01 Ergometrine Maleate 

Secondary care use only. 

07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®

Secondary care use only. 

04.07.04.01 Ergotamine Tartrate Migril®

For use in secondary care only.

Not included in Migraine: Acute Therapy Guidelines (Adult).

08.01.05 Eribulin Halaven®

Red Traffic Light  For treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens as per NICE TA423.

APCO January 2017.

Black Traffic Light  Not recommended for treating locally advanced or metastatic breast cancer after 1 year chemotherapy regimen as per NICE TA515. 

APCO May 2018. 

08.01.05 Erlotinib Tarceva®

Red Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer as per NICE TA258 (APCO September 2012).


Black Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK NEGATIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • Monotherapy for maintenance treatment of non-small-cell lung cancer as per NICE TA227 (APCO September 2011).

05.01.02.02 Ertapenem Invanz®

Secondary care use only. 

APCO July 2010.

06.01.02.03 Ertugliflozin Steglatro®

Second SGLT2i option as monotherapy or with metformin for treating type 2 diabetes, in line with NICE TA 572.

To review the formulary position when cardiovascular outcome data is available. See SGLT2i checklist, patient information leaflet on DKA risk and OCCG letter to clinicians

APCO May 2019.

05.01.05 Erythromycin 

Green Traffic Light  In line with Guidelines for Antibiotic Prescribing in the Community 2018.

Amber Traffic Light  Prokinetic erythromycin should only be used in critically ill patients when other treatments have failed due to risk of resistance - UKMI Q&A dose advice.

13.06.02 Erythromycin 

Alternative regimen for moderate acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

04.03.03 Escitalopram 

Alternative SSRI for Generalised Anxiety Disorder when sertraline has been ineffective (second line). See Primary Care Generalised Anxiety Disorder Guideline for Adults and Older Adults.

APCO September 2017.

04.08.01 Eslicarbazepine Zebinix®

Suitable for continuation in primary care following initiation by Epileptologists only.

For adjunctive treatment in adults as a 3rd line treatment those who have failed treatment with at least 3 drugs. Eslicarbazepine will be adjunctive therapy with the aim of replacing one of the patient's pre-existing anti-epileptic drugs. 

APCO March 2017.

02.04 Esmolol 

Specialist prescribing only.

01.03.05 Esomeprazole 

Esomeprazole 40mg tablets only, can be used for patients with significant symptoms requiring very high dose PPI treatment.

APCO March 2011.

01.03.05 Esomeprazole 

For use in enteral tube patients where a small tube is being used or where blockage problems have occurred with lansoprazole orodispersible tablets/omeprazole dispersible tablets.

APCO July 2013.

08.01.01 Estramustine Phosphate Estracyt®

Secondary care use only.

APCO July 2008.

10.01.03 Etanercept Enbrel®

For the treatment of:

    • Ankylosisng spondylitis and non-radiographic axial spondyloarthritis as per NICE TA383 (APCO March 2016).
    • Juvenile arthritis as per NICE TA35 (APCO January 2016). Funded by specialised commissioning.
    • Psoriatic arthritis as per NICE TA199 (APCO September 2010). For sequential use please refer to Clinical Commissioning Policy 268A.
    • Rheumatoid arthritis as per NICE TA375 (APCO March 2016) and TA195 (APCO September 2010). Also see Clinical Commissioning Policy 201D.

 

13.05.03 Etanercept 

For the treatment of:

    • Psoriasis as per NICE TA103.
    • Plaque psoriasis in children and young people as per NICE TA455. Funded by specialised commissioning. (APCO September 2017).

 

09.05.01.02 Etelcalcetide Parsabiv®

For treating secondary hyperparathyroidism as per NICE TA448.

Funded by specialised commissioning. 

APCO July 2017.

05.01.09 Ethambutol  

Secondary care use only. 

APCO July 2010.

07.03.01 Ethinylestradiol / levonorgestrel phased pill TriRegol®, Logynon®

Phasic standard strength (21 day preparation).

TriRegol® is more cost-effective than Logynon®.

07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20®

Monophasic low strength (21 day preparation).

Loestrin 20® is the most cost-effective monophasic low strength (21 day) preparation.

07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel® 20/150, Alenini®, Mercilon®

Monophasic low strength (21 day preparation).

Gedarel® 20/150 is the most cost-effective preparation.

07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg Millinette® 20/75, Femodette®, Juliperla®, Sunya®

Monophasic low strength (21 day preparation).

Millinette® 20/75 and Juliperla® are the most cost-effective options.

07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel® 30/150, Marvelon®, Cimizt®

Monophasic standard strength (21 day preparation).

Gedarel® 30/150 and Cimizt® are more cost-effective than Marvelon®.

07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette® 30/75, Femodene®,Sofiperla®, Katya®

Monophasic standard strength (21 day preparation).

Millinette® 30/75 and Sofiperla® are the most cost-effective options. 

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30®, Levest®, Ovranette®

Monophasic standard strength combined oral contraceptive (21 day preparation).

Levest® is the most cost-effective monophasic standard strength (21 day) preparation. 

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Microgynon 30 ED®

Monophasic standard strength (28-day ‘Every day’ preparation).

Microgynon 30 ED® is more cost-effective than Femodene ED®

07.03.01 Ethinylestradiol 30mcg / norethisterone 1.5mg Loestrin 30®

Monophasic standard strength (21 day preparation).

07.03.01 Ethinylestradiol 30mcg/drospirenone 3mg Yasmin®

Restricted use for women who are unable to tolerate alternative combined oral contraceptives.

APCO January 2011.

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin®

Monophasic standard strength (21 day preparation).

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor®

Monophasic standard strength (21 day preparation).

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique®, Cilest®, Lizinna®

Monophasic standard strength (21 day preparation).

Cilique® is the most cost-effective option. 

Cilest® will be discontinued with effect from July 2019. Current supplies are expected to last until mid-July 2019.

 

08.03.01 Ethinylestradol 

Suitable for continuation in primary care following specialist initiation.

04.08.01 Ethosuximide 

Suitable for continuation in primary care following specialist initiation or recommendation.

10.01.01 Etodolac 

Suitable for prescribing in primary care following specialist recommendation by rheumatologist.

15.01.01 Etomidate Hypnomidate®

Specialist prescribing only.

07.03.02.02 Etonorgestrel Nexplanon®

Provides contraception for up to 3 years. 

APCO September 2010. 


MHRA/CHM advice (June 2016):

There have been rare reports of Nexplanon® implants reaching the lung via the pulmonary artery. An implant that cannot be palpated at its insertion site should be located and removed as soon as possible; if unable to locate implant within the arm, the MHRA recommends using chest imaging. Correct subdermal insertion reduces the risk of these events.

08.01.04 Etoposide 

Secondary care use only. 

APCO July 2008.

09.01 Etoricoxib 

Amber Traffic Light For pain relief in patients with an inherited bleeding disorder in line with Amber Continuation Guideline.

Initiated by haemophilia clinic, in line with guidelines. GP will need to check BP prior to month 2 prescription.

APCO September 2018.

 

10.01.01 Etoricoxib Arcoxia®

For use in osteoarthritis and rheumatoid arthritis as per NICE guidelines only.

05.03.01 Etravirine Intelence®

For use by Infectious Diseases and Genito-urinary Medicine only.  

Funded by specialised commissioning.

APCO September 2005.

08.01.05 Everolimus 

Red Traffic Light  For:

  • Treating advanced breast cancer in combination with exemestane after endocrine therapy as per NICE TA421 (APCO January 2017).
  • Treating advanced renal cell carcinoma after previous treatment as per NICE TA432 (APCO March 2017).
  • Use with sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease as per NICE TA449 (APCO July 2017). 
  • SEGA-TS, agreed at MMTC in October 2018 (APCO November 2018).

Funded by specialised commissioning.

Black Traffic Light  Not recommended for renal transplant patients as per NICE TA481 and TA482.

APCO November 2017.

02.12 Evolocumab Repatha®

For treating primary hypercholesterolaemia and mixed dyslipidaemia as per NICE TA394.

APCO July 2016.

08.03.04.01 Exemestane 

Amber Traffic Light  Suitable for prescribing in primary care following Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112. In line with Endocrine Therapy in Breast Cancer Guidelines.

APCO May 2007.

Red Traffic Light  In combination with everolimus for treating advanced breast cancer after endocrine therapy as per NICE TA421. In line with Endocrine Therapy in Breast Cancer Guidelines.

APCO January 2017.

06.01.02.03 Exenatide Byetta▼®

Existing patients only (unless high CV risk) in line with updated GLP-1 receptor agonist guidelines

See patient agreement form.

APCO September 2019.

06.01.02.03 Exenatide prolonged release Bydureon▼®

Restricted to existing patients only.

Prescribe semaglutide as first line prolonged release glucagon–like peptide (GLP-1) receptor agonist treatment in line with GLP-1 receptor agonist guidelines. Existing patients who meet NICE criteria for continuation can continue with treatment.

Not included in the GLP-1 receptor agonist guidelines. See patient agreement form.

APCO September 2019.

02.12 Ezetimibe Ezetrol®

For treating primary heterozygous-familial and non-familial hypercholesterolaemia as per NICE TA385.

Decision to start ezetimibe should be made in conjunction with specialist advice oxon.diabetes_lipidsadvice@nhs.net.

See Lipid Modification Guidance.

APCO July 2016.

02.11 Factor IX Fraction, Dried 

Specialist prescribing only.

Funded by specialised commissioning.

02.11 Factor VIIa (Recombinant) Novo 7®

Specialist prescribing only.

Funded by specialised commissioning.

02.11 Factor VIII Fraction, Dried 

Specialist prescribing only.

Funded by specialised commissioning.

02.11 Factor VIII Inhibitor Bypassing Fraction (FEIBA) 

Specialist prescribing only.

Funded by specialised commissioning.

02.11 Factor XIII Fraction, Dried 

Specialist prescribing only.

Funded by specialised commissioning.

05.03.02.01 Famciclovir Famvir®

Treatment for Herpes Zoster or shingles if compliance a problem, as ten times cost. In line with Guidelines for Antibiotic Prescribing in the Community 2018.

10.01.04 Febuxostat Adenuric®

For the management of hyperuricaemia in people with gout who are unable to take or intolerant to allopurinol as per NICE TA164.

APCO March 2010.

02.12 Fenofibrate 

Decision to start a fibrate should be made in conjunction with specialist advice oxon.diabetes_lipidsadvice@nhs.net.

See Lipid Modification Guidance.

04.07.02 Fentanyl Fencino®

Restricted for patients who have stable pain and are unable to take medication orally. In line with Opioid Prescribing Guidelines for Non Cancer Pain.

NB. Fentanyl is a very strong opioid, e.g. 50mcg/hr patch = 120mg morphine daily (Fentanyl conversion ratio table is available in the guideline).

See Good Practice Guidance: Use of Transdermal Fentanyl Patches and record sheet.

APCO September 2015. 

04.07.02 Fentanyl 

For acute severe pain in adolescents at Helen House (End of Life). 

APCO May 2018. 

 

04.07.02 Fentanyl  Ionsys®

For moderate to severe acute post-operative pain.

APCO May 2008.

15.01.04.03 Fentanyl injection 

Specialist prescribing only.

09.01.01.02 Ferric Carboxymaltose Ferinject®

Secondary care use only. 

09.01.01.01 Ferrous Fumarate 

Available as a tablet and oral solution.

Ferrous fumarate 140mg/5ml oral solution should be reserved for children and patients with swallowing difficulties.

09.01.01.01 Ferrous Gluconate 
09.01.01.01 Ferrous Sulphate 
07.04.02 Fesoterodine Toviaz®

Second-line option if tolterodine tolerated but not effective and mirabegron is contra-indicatedin line with The Management of Over Active Bladder Syndrome Guidelines.

APCO March 2017.

03.04.01 Fexofenadine 

Restricted for use where cetirizine, loratadine and chlorphenamine have been tried or are not suitable. 

APCO July 2014. 

For spontaneous urticaria in line with Management Guideline for Spontaneous Urticaria with/without Angioedema in Adults

05.01.07 Fidaxomicin Dificlir®

Secondary care use only for recurrent clostridium difficile infection.

See Guidelines for Antibiotic Prescribing in the Community 2018.

APCO March 2014.

13.02.01 Fifty:50® ointment 

See Emollient Prescribing Guidelines.

Prescribe by brand. Price will vary if prescribed as 50:50 or generically.

APCO March 2020.

09.01.06 Filgrastim 

For neutropenia.

Funded by specialised commissioning.

APCO September 2007.

06.04.02 Finasteride 
08.02.04 Fingolimod 

For the treatment of highly active relapsing-remitting multiple sclerosis as per NICE TA254.

Funded by specialised commissioning.

APCO May 2012.

A5.03.04 Flaminal Forte Gel 

Secondary care Tissue Viability use only. MMTC Oct 19.

APCO November 2019.

A5.03.04 Flaminal Hydro Gel  

Secondary care Tissue Viability use only. MMTC Oct 19.

APCO November 2019.

02.03.02 Flecainide 

Secondary care use only.

02.03.02 Flecainide 

Suitable for continuation in primary care following initiation by a cardiologist.

01.06.05 Fleet Phospho-soda® 

Oral solution. Secondary use only for bowel evacuation before colonic surgery, colonoscopy or radiological examination.

13.04 Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution®

Mild

13.04 Flucinolone Acetonide 0.025% Synalar®

Available in cream, gel and ointment. 

Potent

05.01.01.02 Flucloxacillin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.02 Fluconazole 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.02 Fluconazole 

Secondary care use only. 

APCO July 2010.

07.02.02 Fluconazole 

For the treatment of vaginal candidiasis and recurrent infections, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

12.03.02 Fluconazole 

Second line treatment for oral candidiasis, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.02 Flucytosine Ancotil®

Secondary care use only. 

APCO July 2010.

08.01.03 Fludarabine Phosphate Fludara®

For the treatment of B-cell chronic lymphocytic leukaemia as per NICE TA29.

APCO July 2008.

06.03.01 Fludrocortisone 

Suitable for continuation in primary care following specialist initiation.

13.04 Fludroxycortide 

Agreed at MMTC for Eczema, dermatitis and hypergranulation. Hospital use only.

APCO September 2019.

15.01.07 Flumazenil 

Specialist prescribing only.

12.01.01 Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform®

Note: Clioquinol stains skin and clothing.

04.07.04.02 Flunarizine 5mg 

For migraine prophylaxis (unlicensed and named patient only) in line with Migraine: Adult Prophylactic Therapy Guidelines.

APCO January 2016.

11.04.01 Fluocinolone Acetonide Intravitreal Implant Iluvien®

Red Traffic Light For treating

  • Chronic diabetic macular oedema after an inadequate response to prior therapy as per NICE TA301 (APCO January 2014).
  • Recurrent non-infectious uveitis as per NICE TA590 (APCO September 2019).

Black Traffic Light Not recommended for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy, in line with NICE TA613.

APCO January 2020.

11.08.02 Fluorescein Anatera®

Secondary care use only, restricted for angiography (eye).

  • Injection 10% for fluorescein angiography of the ocular fundus.
  • Injection 20% (Unlicensed Product)

11.08.02 Fluorescein Sodium 

Preservative free Minims® for diagnostic use only.

11.04.01 Fluorometholone FML®

Suitable for prescribing in primary care following specialist recommendation.

08.01.03 Fluorouracil 

Secondary care use only. 

13.08.01 Fluorouracil and Salicylic acid Actikerall® cutaneous solution

For single lesions or hyperkeratotic lesion in line with Oxfordshire Solar Keratosis Primary Care Treatment Pathway.

APCO November 2015.

13.08.01 Fluorouracil cream Efudix®

First-line for multiple lesions in line with Oxfordshire Solar Keratosis Primary Care Treatment Pathway.

APCO November 2015.

04.03.03 Fluoxetine 

Green Traffic Light  Second choice for depression if no response or not tolerating first choice anti-depressants. Long half life. Higher risk of interactions due to CYP2D6 inhibition. See Prescribing Guidelines for the Management of Moderate to Severe Depression.

Amber Traffic Light  Suitable for prescribing in primary care following specialist recommendation for hypersexuality (unlicensedunlicensed).

Doses of 20mg or greater should be prescribed as capsules.

APCO January 2016.

04.03.03 Fluoxetine 

Oxford Health Drugs & Therapeutics Group Decision: for patients with swallowing difficulties, or for patients starting at 10mg (eg CAHMS patients), Olena (a scored dispersible 20mg fluoxetine tablet) should be prescribed in preference to fluoxetine liquid as the community price of the liquid can be double the price of the dispersible tablet. 

Unless liquid is indicated, doses of 20mg or greater should be prescribed as capsules.

See Prescribing Guidelines for the Management of Moderate to Severe Depression.

04.02.01 Flupentixol Depixol®

Suitable for continuation in primary care following specialist recommendation.

04.03.04 Flupentixol Fluanxol®

Suitable for prescribing in primary care following specialist recommendation.

04.02.02 Flupentixol Decanoate Depixol®

Suitable for continuation in primary care following specialist initiation. 

04.02.02 Fluphenazine Decanoate Modecate®

*Product discontinued*

Suitable for continuation in primary care following specialist initiation. 

Fluphenazine depot is discontinued existing stocks will expire in August 2019 (25mg/ml) and August 2020 (100mg/ml).

** Please do not start any new patients on fluphenazine depot **

All patients currently receiving fluphenazine depot should be reviewed at the earliest opportunity so that an arrangements can be made to switch to an alternative antipsychotic treatment.

 

10.01.01 Flurbiprofen 

Restricted for use in Palliative Care only.

08.03.04.02 Flutamide 

Suitable for continuation in primary care following initiation in secondary care by urology or oncology.

03.02 Fluticasone Furoate & Vilanterol Relvar Ellipta®

Green Traffic Light  For asthmatic patients when medium or high dose ICS/LABA required as per Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

Restricted Item Brown Traffic Light  Restricted in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

03.02 Fluticasone Furoate & Vilanterol Relvar Ellipta®

For asthmatic patients when medium or high dose ICS/LABA required as per Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

03.02 Fluticasone Furoate & Vilanterol & Umeclidinium Trelegy Ellipta®

Restricted in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO January 2018.

12.02.01 Fluticasone furoate 27.5mcg Avamys®

Beclomethasone (first line) and mometasone (second line) are more cost effective preparations.

APCO March 2012.

03.02 Fluticasone Propionate Flixotide®

Flixotide® should not be initiated for new patients for asthma.

People whose treatment with Flixotide® is not recommended in Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

12.02.01 Fluticasone Propionate Flixonase Nasule®

Restricted prescribing:

  • After a 6 week trial of steroid nasal spray for nasal polyps; second line fluticasone nasules for 6 weeks then review.
  • Patients with hypo osmia - 6 week course to try and recover the sense of smell.
  • ASA (Aspirin Sensitive Asthma) phenotype. It is often preferable to maintain these patients on a high topical steroid dose (nasules) - sometimes indefinitely as well as using other medications.


APCO January 2010.

12.03.01 Fluticasone Propionate Flixonase Nasule®

Secondary care use only as a mouthwash for a variety of oral mucosal diseases. Also available for use by ENT surgery. 

APCO March 2017.

13.04 Fluticasone Propionate Cutivate®

Cream 0.05%, Ointment 0.005%

Potent

03.02 Fluticasone Propionate and Salmeterol Seretide®50

For asthma see Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO September 2017.

03.02 Fluticasone Propionate and Salmeterol AirFluSal® MDI

In asthma patients when medium or high dose ICS/LABA required as per Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

Available as: 

  • Fluticasone propionate 250 microgram/ Salmeterol 25 microgram
  • Fluticasone propionate 125 microgram/ Salmeterol 25 microgram

APCO September 2017.

03.02 Fluticasone Propionate and Salmeterol Seretide®

Restricted for existing patients only.

NB: Seretide® 500 accuhaler is not included in Guidance on COPD Management in Primary care - Inhaled Therapies.

NB: Only Seretide® 50 evohaler is included in the Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

03.02 Fluticasone Propionate and Salmeterol AirFluSal Forspiro®

For COPD - For patients on existing seretide accuhaler therapy only. Generic equivalent of seretide® 500 accuhaler.

APCO January 2016.

NB. For Asthma - Not included in Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

04.03.03 Fluvoxamine Maleate 

Suitable for prescribing in primary care following specialist recommendation.

Highest incidence of gastric adverse effects. Risk of drug interactions.

See Prescribing Guidelines for the Management of Moderate to Severe Depression.

09.01.02 Folic Acid 
02.08.01 Fondaparinux Arixtra®

Secondary care use only. 

A2.02.02.03 Foodlink® Complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Foodlink® Complete with Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

03.01.01.01 Formoterol fumarate Easyhaler 12micrograms/dose

Formoterol Easyhaler® should not be initiated for new patients for COPD or asthma.

People whose treatment with Formoterol easyhaler® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

03.01.01.01 Formoterol fumarate Oxis® Turbohaler

For COPD patients use Oxis® 12 Turbohaler in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

03.01.01.01 Formoterol Fumarate Atimos® Modulite

Atimos® should not be initiated for new patients for COPD or asthma.

People whose treatment with Atimos® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

03.02 Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide  Trimbow® Inhaler

Triple therapy '3 in 1' inhaler for COPD, for use in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

Another option in place of current fostair/ spiriva respimat.

APCO November 2017.

A2.02.02.03 Forticreme® Complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.01.02 Fortijuce®  

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.02 Fortimel® Regular 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.03.03 Fortini 

Suitable for continuation in primary care following recommendation from a specialist or dietitian only.

A2.01.03.03 Fortini Multifibre 

Suitable for continuation in primary care following recommendation from a specialist or dietitian only.

A2.02.02.03 Fortisip Compact Protein 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fortisip® Compact 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fortisip® Compact Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fortisip® Extra 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fortisip® Yoghurt Style 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fortisip® Bottle 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fortisip® Multi Fibre Savoury flavours

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fortisip® Range 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

05.03.01 Fosamprenavir Telzir®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

APCO September 2005.

04.06 Fosaprepitant Ivemend®

IV prodrug of aprepitant. For nil-by-mouth patients to prevent nausea and vomiting associated with highly emetogenic chemotherapy not responding to standard antiemetic therapy. 

05.03.02.02 Foscarnet Sodium Foscavir®

Secondary care use only. 

APCO July 2010.

05.01.07 Fosfomycin 3g sachets 

Oral fosfomycin is the third or forth line option for patients with an acute, uncomplicated urinary tract infection, In line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO July 2018.

 

06.01.06 FreeStyle Libre® 

Prescribers in primary care are requested to only prescribe Freestyle Libre® sensors on an NHS prescription, in line with OCCG policy, following receipt of an NHS diabetes specialist clinic request accompanied by a completed patient/carer agreement form. Prescribing should only be undertaken for 6 months unless the clinic confirms continuation for individual patients.

NB. Ensure patient agreement form is completed jointly by patient and NHS diabetes specialist:

APCO January 2018.

A2.02.02.03 Fresubin Powder Extra 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Fresubin® 1800 Complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fresubin® 2 kcal Drink 

Brown Traffic Light  Restricted for use only where a patient is under a specialist/dietitian. 2kcal/ml supplements can be used to reduce the volume in bolus feeding via PEG tube or in fluid restricted patients, such as ascites in liver disease. See Clinical Commissioning Policy 277

APCO July 2014.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fresubin® 2 kcal Fibre Drink 

Brown Traffic Light  Restricted for use only where a patient is under a specialist/dietitian. 2kcal/ml supplements can be used to reduce the volume in bolus feeding via PEG tube or in fluid restricted patients, such as ascites in liver disease. See Clinical Commissioning Policy 277.

APCO July 2014.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.01 Fresubin® 2250 complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.03 Fresubin® Creme 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.01 Fresubin® Energy 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fresubin® Energy 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.01 Fresubin® Energy Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fresubin® Energy Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.01 Fresubin® HP Energy 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Fresubin® 1000 Complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Fresubin® 1200 Complete 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.01.02 Fresubin® Jucy 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.02.02.01 Fresubin® Protein Energy Drink 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

04.07.04.01 Frovatriptan 

For recurrent migraine in line with Migraine: Acute Therapy Guidelines (Adult).

APCO November 2016. 

02.02.02 Furosemide 

First choice diuretic for the management of heart failure. See The Management of Heart Failure in Primary Care. 

11.03.01 Fusidic Acid 1% Gel 

Alternative to chloramphenicol for empirical treatment in patients who:

    • Are pregnant.
    • Have a personal or family history of blood dyscrasias, such as aplastic anaemia.
    • Are intolerant of chloramphenicol.

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

13.10.01.02 Fusidic Acid 2% Fucidin®

For treatment of impetigo if localised lesions, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

04.07.03 Gabapentin 

Use capsules as tablets are considerably more expensive.

See Guidelines for the Management of Neuropathic Pain in Primary Care.

APCO March 2017.

04.08.01 Gabapentin 

Suitable for continuation in primary care following specialist initiation or recommendation.

04.11 Galantamine 

For the treatment of Alzheimer's disease following recommendation by specialist or clinician with specialist expertise, except for practices signed up to Primary Care Memory Assessment Service (PCMAS) who may initiate treatment.

See Dementia Prescribing Guidelines and Clinical Commissioning Policy 134B

APCO September 2018.

05.03.02.02 Ganciclovir Cymevene®

Secondary care use only. 

APCO July 2010.

11.03.03 Ganciclovir 0.15% Gel Virgan®

For acute herpetic keratitis. To replace aciclovir eye ointment which is no longer available.

APCO July 2019.

16.01 Gastrografin 

For short bile obstruction.

APCO May 2018.

01.01.02 Gaviscon Infant® 

 

01.01.02 Gaviscon® Advance 

Available to purchase over the counter.

Anyone requiring more than occassionally is likely to be more suitable for a PPI or equivalent, in line with Clinical Commissioning Policy 88D

08.01.05 Gefitinib Iressa®

Red Traffic Light  For the first-line treatment of locally advanced or metastatic non-small-cell lung cancer as per NICE TA192.

Funded by specialised commissioning.

APCO September 2010.

Black Traffic Light  Not recommended for treating non-small-cell lung cancer that has progressed after prior chemotherapy as per NICE TA374.

APCO January 2016.

09.02.02.02 Gelatin Gelofusine®

Secondary care use only. 

09.02.02.02 Gelatin Gelaspan®

Secondary care use only. 

12.03.01 Gelclair® 

Oral gel (sachets) for the treatment of oral mucositis in oncology. 

Gelclair® is classed as a medical device.

08.01.03 Gemcitabine Gemzar®

Red Traffic Light  For the treatment of:

  • Pancreatic cancer and metastatic breast cancer as per NICE TA25 and NICE TA116 (APCO March 2008).
  • Untreated metastatic pancreatic cancer in combination with paclitaxel as albumin-bound nanoparticles as per NICE TA476 (APCO November 2017).

Funded by specialised commissioning.

Black Traffic Light  Not recommended for the following:

  • Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer as per NICE TA389 (APCO May 2016).
  • Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer as per NICE TA285 (APCO July 2013).
  • Nab-paclitaxel (Abraxane) with gemcitabine in previously untreated metastatic pancreatic cancer as per NICE TA360 (APCO November 2015).
08.02.03 Gemtuzumab oxogamicin  Mylotarg®

For untreated acute myeloid leukaemia as per NICE TA545. Funded by specialised commissioning.

APCO January 2019.

 

05.01.04 Gentamicin 

Secondary care use only. 

APCO May 2012.

12.01.01 Gentamicin 0.3% Ear drops Genticin®
11.03.01 Gentamicin 0.3% Eye Drops 

Suitable for prescribing in primary care following specialist recommendation.

12.03.05 Glandosane® 

May be prescribed under ACBS for patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome, spray onto oral and pharyngeal mucosa as required.

08.02.04 Glatiramer Acetate Copaxone®

Red Traffic Light  For treating multiple sclerosis as per NICE TA527.

Funded by specialised commissioning.

APCO July 2018.

05.03.03.02 Glecaprevir and Pibrentasvir Maviret®

For treating chronic hepatitis C as per NICE TA499.

APCO March 2018.

06.01.02.01 Glibenclamide 

Unusual regime to use, review patient. Gliclazide is first line sulfonylurea.

APCO September 2016.

06.01.02.01 Gliclazide 

Gliclazide is first line sulfonylurea.

APCO September 2016.

06.01.02.01 Glimepiride 

Unusual regime to use, review patient. Gliclazide is first line sulfonylurea.

APCO September 2016.

06.01.02.01 Glipizide 

Unusual regime to use, review patient. Gliclazide is first line sulfonylurea.

APCO September 2016.

06.01.04 Glucagon GlucaGen® HypoKit

Can be initiated in primary care but seek specialist support to manage hypoglycaemia.

APCO March 2020.

06.01.01.03 GlucoRx FinePoint 

BD Viva is first-line choice for insulin pen needles.

APCO November 2018.

09.02.02.01 Glucose Intravenous 

Secondary care use only. 

A2.06.01 Gluten Free Products 

Brown Traffic Light  Restricted in line with Clinical Commissioning Policy 42E and Clinical Commissioning Policy 88D. Products other than bread and flour are not recommended for prescribing. 

See guidance on gluten free prescribing

APCO September 2012.

Black Traffic Light  For Autism as not prescribed on the NHS as defined by DoH.

APCO January 2003.

01.06.02 Glycerol (Glycerin) 

Moisten suppository with water before use. Available to purchase over the counter. 

01.07.04 Glyceryl trinitrate 0.4% rectal ointment Rectogesic®

Restricted use for anal fissure after lifestyle advice or use of topical anaesthetic prior to specialist referral. Licensed and easily available.

APCO June 2007.

02.06.01 Glyceryl Trinitrate Sublingual spray 
02.06.01 Glyceryl Trinitrate Sublingual tablets 
02.06.01 Glyceryl Trinitrate Transdermal patch 

Only for those who cannot have oral therapy.

07.04.04 Glycine 1.5% 

Secondary care use only. 

15.01.03 Glycopyrronium bromide  

Red Traffic Light  For hypersalivation in mental health patients. 

APCO September 2013.

Amber Traffic Light  For hypersalivation in neurology patients. 

APCO September 2013.

Amber Traffic Light Excessive respiratory secretions in palliative care.

NB. Licensed solution is available as 'glycopyrronium bromide 1mg/5ml oral solution sugar free'. This comes in 150ml bottle from the manufacturer Colonis Pharma Ltd.

01.02 Glycopyrronium Bromide 320 mcg/ml Sialanar®

Suitable for prescribing following initiation or recommendation from secondary care.

Licensed product (in children) for symptomatic treatment of severe sialorrhoea. Use in children and adults in line with NICE guidance (NG62, NG42 and NG31). 

NB. More cost-effective than unlicensed product. 

APCO May 2017. 

01.05.03 Golimumab Simponi®

For treating moderately to severely active ulcerative colitis after the failure of conventional therapy as per NICE TA329. Also see Clinical Commissioning Policy 263 (ulcerative colitis in adults).

APCO March 2013.

10.01.03 Golimumab Simponi®

For the treatment of:

  • Psoriatic arthritis as per NICE TA220.  For sequential use please refer to Clinical Commissioning Policy 268A (APCO May 2011).
  • Rheumatoid arthritis as per NICE TA225 and NICE TA375. Also see Clinical Commissioning Policy 201D (APCO March 2011 and 2016).
  • Ankylosing spondylitis as per NICE TA383 (APCO March 2016). 
  • Non-radiographic axial spondyloarthritis as per NICE TA497 - Fast track (APCO February 2018).
06.05.01 Gonadorelin 

Specialist prescribing only.

08.03.04.02 Goserelin 10.8mg Zoladex LA®

For Central Precocious Puberty (CPP) see section 06.07.02.

Suitable for prescribing in primary care following specialist recommendation (for indications other than CPP).

First-line gonadotropin-releasing hormone (GnRH) analogue for the treatment of prostate cancer is triptorelin SR 22.5mg. See GnRH analogues in prostate cancer guidelines. NB. This is a 12-weekly preparation.

APCO January 2014.

08.03.04.02 Goserelin 3.6mg Zoladex®

For Central Precocious Puberty (CPP) see section 06.07.02.

Suitable for prescribing in primary care following specialist recommendation (for indications other than CPP).

First-line gonadotropin-releasing hormone (GnRH) analogue for the treatment of prostate cancer is triptorelin SR 22.5mg. See GnRH analogues in prostate cancer guidelines. NB. This is a 4-weekly preparation.

APCO January 2014.

For treatment of breast cancer, in line with Endocrine Therapy in Breast Cancer Guidelines. 

03.04.02 Grass pollen extract Grazax®

Specialist prescribing only for paediatric patients with severe allergic rhinitis where other treatments have failed.

APCO January 2019.

05.02 Griseofulvin 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

04.04 Guanfacine Intuniv®

Secondary care prescribing only for attention deficit hyperactivity disorder.

APCO May 2016.

13.05.03 Guselkumab Tremfya®

For treating moderate to severe plaque psoriasis as per NICE TA521.

APCO July 2018.

09.08.02 Haem Arginate Normosang®

Secondary care use only. 

06.01.01.03 HaemoFine 

BD Viva and GlucoRx FinePoint are first-line choices for insulin pen needles.

APCO November 2016.

14.04 Haemophilus influenzae type B Menitorix®
03.01.05 Haleraid® 

Restricted to secondary care only for patients with dexterity problems. 

NB: Not available on FP10. Patients may be advised to purchase in primary care.

04.02.01 Haloperidol 

Red Traffic Light  For rapid tranquilisation: Hospital use only.

Green Traffic Light  For use in palliative care

04.02.01 Haloperidol 

Suitable for continuation in primary care following specialist recommendation.

Oral and IM doses are NOT equivalent. 

04.02.02 Haloperidol Haldol Decanoate®

Suitable for continuation in primary care following specialist initiation.

This preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

02.08.01 Heparin 

Secondary care use only. 

02.08.01 Heparin 

Suitable for continuation in primary care following specialist initiation.

14.04 Hepatitis A vaccine Single Component Avaxim®
14.04 Hepatitis A vaccine Single Component Epaxal®
14.04 Hepatitis A vaccine Single Component Havrix Monodose®
14.04 Hepatitis A vaccine Single Component Vaqta® Paediatric
14.05.02 Hepatitis B immunoglobulin HBIG

Secondary care use only. 

12.03.04 Hexetidine Oraldene®

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

 

13.11.02 Hibitane Obstetric® 

For use in obstetrics and gynaecology as an antiseptic and lubricant (for application to skin around vulva and perineum and to hands of midwife or doctor).

Cream contains Chlorhexidine Gluconate Solution 5% (≡ Chlorhexidine Gluconate 1%).

13.10.05 Histoacryl® 

Histoacryl® tissue adhesive is restricted to secure paediatric epidurals only in secondary care.

16.01 Holoclar 

For treating limbal stem cell deficiency after eye burns as per NICE TA467.

NB. The responsible commissioning body is still to be confirmed for this treatment.

APCO September 2017. 

11.05 Homatropine Eye drops 

Suitable for prescribing in primary care following specialist recommendation.

02.11 Human fibrinogen & thrombin Raplixa®

Specialist prescribing only.

Funded by specialised commissioning.

14.04 Human papilloma virus vaccine Cervarix®
14.04 Human papilloma virus vaccine Gardasil®

Green Traffic Light Vaccine of choice for the national immunisation program as per Green Book.

Red Traffic Light For men who have sex with men (MSM). Prescribed by Specialist Sexual Health Services and HIV clinics. NHS E/PHE funded. 

APCO September 2018.  

10.01 Hyaluronic acid 

For limited use within OUHFT (NOC) as per agreed internal guidelines. 

APCO March 2009.

NB. Hyalgan® was discontinued in September 2013.

10.03.01 Hyaluronidase Hyalase®

Secondary care use only.

02.05.01 Hydralazine 

Use in combination with nitrate for the management of heart failure, see The Management of Heart Failure in Primary Care. 

A5.02.04 Hydrocolloid  

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

01.05.02 Hydrocortisone Colifoam®

First choice steroid foam enema for IBD.

06.03.02 Hydrocortisone 
12.03.01 Hydrocortisone Corlan®

Mucoadhesive buccal tablets (oromucosal tablets) for treatment of mouth ulcers. 

10.01.02.02 Hydrocortisone acetate Hydrocortistab®
06.03.02 Hydrocortisone sodium phosphate Efcortesol®

Available as a ready to use solution, so may be more suitable for GP emergency bags than Solu-Cortef®.

06.03.02 Hydrocortisone sodium succinate Solu-Cortef®

Available as a powder to be mixed with water for injection before use.

13.04 Hydrocortisone 0.25% with Crotamiton 10% Eurax-HC®

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

13.04 Hydrocortisone 0.5%/ 1%  

First-line treatment for mild eczema, in line with Guidelines for the use of Corticosteroids in Atopic Eczema.

1% cream and ointment are available to purchase over the counter, except where a larger quantity than 30g or application on the face is required, in line with Clinical Commissioning Policy 88D.

 Mild

13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

Mild with antifungal

13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

Mild with antifungal

13.04 Hydrocortisone 1% with Urea 10% Alphderm®
13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H®

Short term use in infected eczema where oral antibiotics are contraindicated.

Mild with antimicrobial

12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC
13.04 Hydrocortisone Butyrate Locoid®

Available in cream 0.1% (30g and 100g), lipocream 0.1% (30g), ointment 0.1% (30g and 100g) and scalp lotion 0.1% (100g). Please note only lipocream is available at the OUH. 

Potent

A5.02.02 Hydrofilm 

To replace C-view, more cost-effective.

Must be ordered on ONPOS.

APCO November 2019.

A5.02.02 Hydrofilm® Plus 

Use when a waterproof option is necessary.

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

APCO May 2015.

 

13.11.06 Hydrogen Peroxide 1% Crystacide® cream

For superficial bacterial skin infection.

13.11.06 Hydrogen Peroxide Solution BP 

Solution 6% or 3% for skin disinfection, particularly cleansing and deodorising wounds and ulcers.




Can be purchased over the counter. 


13.02.01 Hydromol® Intensive Cream 

In line with OCCG Wound Management Formulary 

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

APCO May 2015.

09.01.02 Hydroxocobalamin 
08.01.05 Hydroxycarbamide 500mg/5ml oral liquid

Secondary care use only. Liquid formulation is not included in the shared care protocols. 

APCO November 2019.

08.01.05 Hydroxycarbamide (Hydroxyurea) Hydrea®

 

 

09.01.03 Hydroxycarbamide (Hydroxyurea) Siklos®

For the treatment of sickle cell disease in adults and children > 12 years old in line with Shared Care Protocol.

NB. ONLY the 100mg and 500mg hydroxycarbamide formulations should be PRESCRIBED for safety reasons.

APCO May 2017.

10.01.03 Hydroxychloroquine 

For use in adult and paediatric rheumatology in line with Shared Care Protocol.

Please see local position statement on Hydroxychloroquine and Retinopathy Screening.

APCO September 2019

13.05.03 Hydroxychloroquine 

For use in adult and paediatric dermatology in line with Shared Care Protocol.

Please see local position statement on Hydroxychloroquine and Retinopathy Screening.

APCO September 2019.

11.08.01 Hydroxypropyl guar Systane®

Restricted for patients who require a preservative formulation, in line with Ocular lubricant prescribing guidelines.

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018. 

11.08.01 Hydroxypropyl Guar Systane®

Third line treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

NB. This product lasts 6 months from opening.

03.04.01 Hydroxyzine 
01.02 Hyoscine Butylbromide Buscopan®
04.06 Hyoscine Hydrobromide 

First line for antipsychotic-induced hypersalivation (unlicensed indication), as per Oxford Health Medicines Information Bulletin - Management of clozapine-induced hypersalivation.

Available to purchase over the counter as Scopoderm® patches, Kwells® and Joy-Rides® for motion sickness. 

11.08.01 Hypromellose 0.3% Eye drops 

Prescribe generically.

First line treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

11.08.01 Hypromellose 0.3% Eye drops Tear-Lac®

Restricted for patients who require a preservative formulation, in line with Ocular lubricant prescribing guidelines.

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018. 

06.06.02 Ibandronic Acid 

Alternative option if Alendronate or Risedronate is not suitable, as per Guidance for Fracture Risk Assessment and Prevention in Primary Care.

APCO May 2018.

06.06.02 Ibandronic Acid 

Suitable for continuation in primary care following specialist initiation:

06.06.02 Ibandronic Acid 3mg injection Bonviva®

For treating osteoporosis in line with Guidance for fracture risk assessment and prevention in primary care, as per NICE TA464.

APCO May 2018.

08.01.05 Ibrutinib Imbruvica®

Red Traffic Light  For treating;

  • Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation as per NICE TA429 (APCO March 2017).
  • Waldenstrom's macroglobulinaemia as per NICE TA491 (APCO January 2018).
  • Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502 (APCO March 2018).

Black Traffic Light  For:

    • Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (with bendamustine and rituximab) NICE TA437 - terminated appraisal (APCO May 2017).
    • Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation as per NICE TA465 - terminated appraisal (APCO September 2017).
    • With rituximab for treating Waldenstrom’s macroglobulinaemia as per NICE TA608 - terminated appraisal (APCO January 2020).
04.07.04.01 Ibuprofen 

For treatment of acute migraine, see Migraine: Acute Therapy Guidelines (Adult)

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

APCO November 2016. 

07.01.01.01 Ibuprofen NeoProfen® injection

Secondary care use in SCBU only.

10.01.01 Ibuprofen 

First line NSAID. 

Available to purchase over the counter for short-term use. 

Only prescribe if more than 28 tablets per month are required for an ongoing basis for a chronic condition, in line with Clinical Commissioning Policy 88D.

10.01.01 Ibuprofen Brufen Retard®

Suitable for prescribing in primary care following specialist recommendation by rheumatologist.

10.03.02 Ibuprofen Gel 

Available to purchase over the counter for short-term use.

Only prescribe if required for a chronic condition that is not expected to improve and where patient is not suitable for oral NSAIDs, in line with Clinical Commissioning Policy 88D.

13.05.01 Ichthammol Ichthopaste®

Suitable for prescribing in primary care following specialist recommendation.

08.01.02 Idarubicin Zavedos®

Secondary care use only. 

APCO July 2008.

02.08 Idarucizumab Praxbind®

For the reversal of the anticoagulant effect of dabigatran.

APCO March 2016.

11.08 Idebenone Raxone®

Secondary care use only. Resricted to Lebers optic atropy neuropathy in connection with MS.

08.01.05 Idelalisib Zydelig®

Red Traffic Light  For treating chronic lymphocytic leukaemia as per NICE TA359.

APCO November 2015.

Black Traffic Light  Not recommended for

  • For treating chronic lymphocytic leukaemia with ofatumumab as per NICE TA469 - terminated appraisal (APCO September 2017).
  • For treating refractory follicular lymphoma as per NICE TA604 (APCO November 2019).
08.01.01 Ifosfamide 

Secondary care use only. 

APCO July 2008.

02.05.01 Iloprost injection  

For use by Vascular Surgery for the treatment of limb threatening ischaemia, and by Rheumatology in Raynaud's Syndrome (unlicensed).

08.01.05 Imatinib Gilvec®

For the treatment of:

  • Gastrointestinal stromal tumours as per NICE TA86 and NICE TA326 (APCO January 2015).
  • Untreated chronic myeloid leukaemia as per NICE TA70 and NICE TA426 (APCO January 2017).
  • Chronic graft versus host disease as per NHS England: 16069/P (APCO September 2017).

Funded by specialised commissioning.

06.01.01.03 IME-FINE 

BD Viva and GlucoRx FinePoint are first-line choices for insulin pen needles.

APCO November 2016.

05.01.02.02 Imipenem with Cilastatin Primaxin®

Secondary care use only. 

APCO July 2010.

04.03.01 Imipramine 

Suitable for continuation in primary care following specialist initiation. 

See Prescribing Guidelines for the Management of Moderate to Severe Depression.

04.07.03 Imipramine 

See Guidelines for the Management of Neuropathic Pain in Primary Care.

APCO March 2017.

13.07 Imiquimod 5% cream Aldara®

Green For superficial basal cell carcinoma.

APCO September 2011.

Red Secondary care use only for patients with recalcitrant external anogenital warts (initiation by GUM consultants only).

APCO August 2007.

 

 

13.08.01 Imiquimod 5% cream  Aldara®

Third-line for multiple lesions in line with Oxfordshire Solar Keratosis Primary Care Treatment Pathway.

APCO November 2015.

13.02.01 imuDERM® emollient 

See Emollient Prescribing Guidelines.

Urea 5% + glycerine 5%. Very competitively priced, effective moisture-preserving emollient.

Natural moisturising factor – constituents of product improve hydration of the stratum corneum.

APCO March 2020.

A5.03.02 Inadine® 

Must be ordered on ONPOS in line with  OCCG Wound Management Formulary.

APCO May 2015. 

02.02.01 Indapamide 

First choice thiazide for treatment of hypertension.

02.02.01 Indapamide MR 
05.03.01 Indinavir Crixivan®

For use by Infectious Diseases.  

Funded by specialised commissioning.

APCO September 2005.

11.08.02 Indocyanine green 

Secondary care use only, as a marking agent during surgery in patients with allergy to iodine.  Angiography / retinal imaging and intraocular visualisation.

07.01.01.01 Indometacin 

Secondary care use only for closure of Patent Ductus Arteriosus (PDA) in premature neonates.

10.01.01 Indometacin 
07.04.01 Indoramin Doralese®

Please note that Tamsulosin M/R capsules are first line.

14.04 Infanrix IPV® 

Contains: Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed).

14.04 Infanrix-IPV+Hib® 

Contains: Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed).

A2.01.03.02 Infatrini® 

Suitable for continuation in primary care following recommendation from a specialist or dietitian only, in line with Clinical Commissioning Policy 250B.

Note: All paediatric related queries from GPs can be sent to oxon.paediatricadvice@nhs.net

APCO September 2017.

A2.03.01 Infatrini® Peptisorb 

High calorie EHF to optimise caloric intake in poor feeders with multiple food intolerances and malabsorption. Suitable for continuation in primary care following initiation or recommendation from a specialist or dietitian only.

See:


Note: All allergy related queries from GPs can be sent to oxon.paedsallergyadvice@nhs.net

APCO September 2017.

01.05.03 Infliximab 

For the treatment of:

10.01.03 Infliximab 

For the treatment of:

    • Rheumatoid arthritis as per NICE TA195 (APCO September 2010) and NICE TA375 (APCO March 2016). Also see Clinical Commissioning Policy 201D.
    • Ankylosing spondylitis or severe non-radiographic axial spondyloarthritis as per NICE TA383 (APCO March 2016).
    • Psoriatic arthritis as per TA199 (APCO September 2010). For sequential use please refer to Clinical Commissioning Policy 268A.

 

13.05.03 Infliximab Remicade®

For the treatment of adults with psoriasis as per NICE TA134. Also see Clinical Commissioning Policy 266D.

APCO March 2008.

14.04 Influenza vaccine 

Cost-effective brands include:

  • Enzira®: 2017 NHS price - £5.25.
  • Influvac®: 2017 NHS Price - £5.22.


NB. Intanza® is black listed, see below for more details.

06.01.01.03 Injection Devices Autopen®
06.01.01.03 Injection Devices HumaPen®
06.01.01.03 Injection Devices JuniorSTAR®
06.01.01.03 Injection Devices NovoPen®
06.01.01.03 Injection Devices ClikSTAR®
09.08.01 Inotersen Tegsedi®

Secondary care prescribing only for treating hereditary transthyretin amyloidosis as per NICE HST9.

Funded by specialised commissioning.

APCO July 2019.

08.01.05 Inotuzumab ozogamicin Besponsa®

For treating relapsed or refractory B-cell acute lymphoblastic leukaemia as per NICE TA541.

Funded by specialised commissioning.

APCO November 2018.

06.01.01.01 Insulin Insuman® Infusat

For use in external portable insulin pumps.

Suitable for prescribing in primary care following recommendation from diabetes specialist only.

06.01.01.01 Insulin Humulin® S

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 Diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin Actrapid®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin Insuman® Rapid

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist type 1 diabetes services in line with national guidance. Type 1 Diabetes is a different disease to type 2 diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin 500units/mL Humulin R®

Suitable for prescribing in primary care following recommendation from diabetes specialist only.

Imported from United States.

06.01.01.01 Insulin Aspart NovoRapid®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin Aspart Fiasp®

Fiasp can be initiated in patients following diabetes specialist (CDS and OUH) recommendation and maintenance of register ONLY IF both the following criteria fulfilled:

  • Patient is currently on a rapid acting insulin analogue (ie Novorapid, Humalog, Apidra)
  • Presence of a mismatch between insulin rise and post prandial glucose rise.

Fiasp® should NOT be used as the first line prandial insulin for any patient with diabetes. 

APCO May 2017. 

06.01.01.01 Insulin bovine Hypurin® Bovine Neutral

Consider asking for specialist review-unusual regime to use.

06.01.01.02 Insulin degludec Tresiba®

Treatment should only be initiated on recommendation from the diabetes specialist team (OCDEM or Community Diabetes Service). Degludec can be considered for type 1 or 2 patients who are having more than 2 hypoglycaemic events per week, or have had more than 1 diabetic ketoacidosis episode in the past 12 months, or require a more flexible dosing interval, or who are on a total long acting insulin dose of more than 80 units per day.

All patients MUST be entered into the national degludec audit. Degludec is available as 100units/ml and 200units/ml, please follow MHRA guidance when prescribing.

APCO January 2017.

06.01.01.02 Insulin degludec Tresiba®

Treatment should only be initiated on recommendation from the diabetes specialist team (OCDEM or Community Diabetes Service). Degludec can be considered for type 1 or 2 patients who are having more than 2 hypoglycaemic events per week, or have had more than 1 diabetic ketoacidosis episode in the past 12 months, or require a more flexible dosing interval.

All patients MUST be entered into the national degludec audit. Degludec is available as 100units/ml and 200units/ml, please follow MHRA guidance when prescribing.

APCO January 2017.

06.01.01.02 Insulin degludec and liraglutide Xultophy®

Initiation by diabetes consultant only with criteria in GLP-1 receptor agonist guidelines.

Also see prescribing information on Xultophy®.

APCO May 2017.

06.01.01.02 Insulin Detemir Levemir®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Insulin Glargine Lantus®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Insulin Glargine Toujeo®

On recommendation of the diabetes specialist team (OCDEM or Community Diabetes Service) for patients who are already on optimised complex regime, who have already tried other insulins (including degludec if patient meets criteria) and on a total long acting insulin dose of more than 80 units per day (or lower if they have very limited injections sites or require 3rd party administration).

APCO January 2017.

06.01.01.02 Insulin Glargine biosimilar 

Note that biosimilar 'Abasaglar' is first line choice for NEW patients if glargine is indicated. Existing patients should not be switched.

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

APCO January 2016.

06.01.01.01 Insulin Glulisine Apidra®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin Lispro Humalog®

Biosimilar Insulin Lispro Sanofi is first line choice for NEW patients if insulin lispro is indicated. Existing patients should not be switched unless in line with an agreed protocol. All prescriptions should be written by brand name.

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.01 Insulin Lispro Sanofi 

Biosimilar Insulin Lispro Sanofi is first line choice for NEW patients if insulin lispro is indicated. Existing patients should not be switched unless in line with an agreed protocol. All prescriptions should be written by brand name.

Green Traffic Light Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

APCO January 2019.

06.01.01.01 Insulin porcine Hypurin® Porcine Neutral

Consider asking for specialist review-unusual regime to use.

06.01.01.02 Insulin Zinc suspension Hypurin®Bovine Lente

Consider asking for specialist review-unusual regime to use.

08.02.04 Interferon Beta-1a Avonex®

For treating multiple sclerosis as per NICE TA527. 

Funded by specialised commissioning.

APCO July 2018.

08.02.04 Interferon Beta-1a Rebif®

For treating multiple sclerosis as per NICE TA527.

Funded by specialised commissioning. 

APCO July 2018.

08.02.04 Interferon Beta-1b Extavia®

For treating multiple sclerosis as per NICE TA527.

Funded by specialised commissioning.

APCO July 2018.

14.05 INTERFERON GAMMA-1b Immukin®

Prescribe by brand.

Secondary care use only. 

09.03 Intralipid 20% 

Secondary care use only. 

16.01 Intratympanic methylprednisolone  Sodium Succinate

For sensorineural hearing loss. Agreed at May MMTC.

APCO July 2019.

07.03.04 Intra-uterine Contraceptive Devices TT 380 Slimline®

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices UT 380 Standard®

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices Flexi-T® 300

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices Flexi-T® + 300

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices GyneFix®

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices Load® 375

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices 

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices Nova-T® 360

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices T-Safe® CU 380 A

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.04 Intra-uterine Contraceptive Devices UT 380 Short®

Funded by Public Health - as per Family Planing Association Guidelines.

07.03.02.03 Intra-uterine Progestogen Only System Levosert®

For women requiring contraception for up to 4 years.

NB. Levonorgestrel-releasing intra-uterine devices vary in licensed indication, duration of use and insertion technique—the MHRA recommends to prescribe and dispense by brand name to avoid inadvertent switching.

Heavy Menstrual Bleeding: For women requiring HMB treatment for up to 4 years. 

APCO March 2018.

07.03.02.03 Intra-uterine Progestogen Only System Jaydess®

As an alternative to Levosert/ Mirena if:

  • The woman has previously used Mirena IUS and experienced
    • discomfort
    • unacceptable symptoms
    • troublesome (symptomatic) ovarian cysts
  • Loss of periods is unacceptable to the woman but heavy periods precludes use of copper IUD.
  • History of breast cancer (for consultation at specialist contraception clinic and following involvement of oncologist)
  • Woman wishes to avoid hormones because of unacceptable side effects with hormones previously.
  • Failure at time of fitting to dilate internal os sufficiently for Mirena Jaydess IUS may be fitted because of narrower diameter.

APCO March 2018

07.03.02.03 Intra-uterine Progestogen Only System Mirena®

Contraception: For women requiring contraception for up to 5 years. Levonorgestrel-releasing intra-uterine devices vary in licensed indication, duration of use and insertion technique—the MHRA recommends to prescribe and dispense by brand name to avoid inadvertent switching.

Heavy Menstrual Bleeding: For women requiring HMB treatment for up to 5 years in line with local Care Pathway and Referral Criteria

Adjunctive progestogen in HRT treatment: in line with Oxfordshire HRT formulary and treatment guidance. Licensed for 4 years for HRT use. 

APCO January 2016. 

06.02.02 Iodine and Iodide 

Specialist prescribing only.

A5.03.02 Iodoflex® 

For short term use. Obtain via the prescription (FP10) route.

Use if honey not tolerated or contraindicated. Only appropriate for use on locally infected wounds with moderate to high exudate levels, in line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

APCO May 2015. 

A5.03.02 Iodosorb® 

For short term use. Obtain via the prescription (FP10) route.

Use if honey not tolerated or contraindicated. Only appropriate for use on locally infected wounds with moderate to high exudate levels, in line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

APCO May 2015. 

08.01.05 Ipilimumab Yervoy®

For previously untreated advanced (unresectable or metastatic) melanoma  as per NICE TA319.

03.01.02 Ipratropium Bromide 
12.02.02 Ipratropium Bromide Rinatec®

Nasal spray 0.03%.

02.05.05.02 Irbesartan 

For patients intolerant of ACE inhibitors due to cough.

09.01.01.01 Iron and Folic Acid Pregaday®
09.01.01.02 Iron Dextran CosmoFer®

Secondary care use only.

09.01.01.02 Iron Sucrose Venofer®

Secondary care use only. 

05.02 Isavuconazole Cresemba®

For treatment of fungal infections if resistance/intolerance to alternatives.

APCO March 2017.

04.03.02 Isocarboxazid 

Suitable for prescribing in primary care following specialist recommendation.

15.01.02 Isoflurane 

Specialist prescribing only.

05.01.09 Isoniazid 

Secondary care use only. 

APCO July 2010.

06.01.01.02 Isophane Insulin Hypurin® Bovine Isophane

Consider asking for specialist review-unusual regime to use.

06.01.01.02 Isophane Insulin Hypurin® Porcine Isophane

Consider asking for specialist review-unusual regime to use.

06.01.01.02 Isophane Insulin Insulatard®

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Restricted Item Brown Traffic Light  Should not usually be used first line in Type 2 Diabetes. See Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Isophane Insulin Humulin® I

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

06.01.01.02 Isophane Insulin Insuman® Basal

Green Traffic Light  Patients with Type 1 Diabetes should have access to specialist Type 1 Diabetes services in line with national guidance. Type 1 Diabetes is a different disease to Type 2 Diabetes with different treatment pathways. Please consider accessing specialist diabetes care for all your patients with Type 1 Diabetes.

Green Traffic Light  First line insulins for Type 2 Diabetes in line with Insulin Initiation and Adjustment in Type 2 Diabetes Primary Care Guidelines.

02.07.01 Isoprenaline 

Specialist prescribing only.

Available from ‘special-order’ manufacturers or specialist importing companies.

 

02.06.01 Isosorbide Mononitrate  
02.06.01 Isosorbide Mononitrate MR 

Currently the most cost effective 60mg MR tablet is Monomil XL 60mg tablets.

A2.01.02.03 Isosource® Energy 

Brown Traffic Light  Restricted for use only where a patient is under a specialist/dietitian. 2kcal/ml supplements can be used to reduce the volume in bolus feeding via PEG tube or in fluid restricted patients, such as ascites in liver disease. See Clinical Commissioning Policy 277

APCO July 2014.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.01 Isosource® Energy Fibre 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

13.06.01 Isotretinoin Isotrex® gel

Specialist prescribing only.

APCO May 2011.

13.06.02 Isotretinoin Capsules

For prescribing by dermatologists only in secondary care for severe acne or acne unresponsive to oral antibiotics after 6 months.

NB. Women of child-bearing potential should be on at least one, or preferably two, complementary forms of effective contraception (e.g. barrier and hormonal) for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. 

APCO May 2011.

01.06.01 Ispaghula Husk Fybogel®, Ispagel® Orange

Available to purchase over the counter. 

05.02 Itraconazole 

Prescribe in line with NICE CKS and Guidelines for Antibiotic Prescribing in the Community 2018.

02.06.03 Ivabradine Procoralan®

Amber Traffic Light 

  • Usually specialist prescribing only for arrhythmia but may be appropriate for shared care where an individual patient specific protocol is agreed (APCO January 2008).
  • For patients with chronic heart failure in line with local Amber Continuation Guideline (APCO September 2018). 

Amber Traffic Light As add on therapy for symptomatic treatment of patients with stable angina in line with Shared Care Protocol.


APCO March 2013.

 

03.07 Ivacaftor 

For the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.

APCO March 2017.

13.10.04 Ivermectin 

Secondary care prescribing only.

APCO July 2010.

13.06 Ivermectin cream Soolantra®

Can be prescribed for mild to moderate Rosacea following specialist recommendation, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018.

08.01.05 Ixazomib Ninlaro®

With lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults as per NICE TA505.

10.01.03 Ixekizumab Taltz®
  • For treating moderate to severe plaque psoriasis as per NICE TA442 (APCO July 2017).
  • For treating active psoriatic arthritis after inadequate response to DMARDs as per NICE TA537 (APCO September 2018).
A2.01.02.01 Jevity® 1.5 kcal 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Jevity® Plus 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Jevity® Plus HP 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

A2.01.02.02 Jevity® Promote 

Brown Traffic Light  In line with Clinical Commissioning Policy 277

APCO May 2017.

Black Traffic Light  For patients in care and nursing homes. Food fortification by care home staff should be used in most cases. Exceptions are PEG tube patients or patients with head and neck cancer or motor neurone disease.

APCO September 2015.

15.01.01 Ketamine injection 

Amber Traffic Light  For use in palliative care in line with patient specific protocol.

APCO July 2016.

Black Traffic Light  For use in chronic pain.

APCO March 2014.

Red Traffic Light  Specialist prescribing only for all other indications.

05.02 Ketoconazole 

Secondary care use only. 

APCO July 2010.

13.10.02 Ketoconazole 

For continuation following specialist recommendation for seborrhoeic dermatitis and pityriasis versicolor.

13.09 Ketoconazole 2% 

For treatment of Pityriasis Versicolor, see Guidelines for Antibiotic Prescribing in the Community 2018. (unlicensed indication – BNF for children is from 5 years).

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

10.03.02 Ketoprofen 2.5% Gel Oruvail ®, Powergel®

First line topical NSAID - one of the most cost-effective topical preparations available. 

APCO January 2013. 

11.08.02 Ketorolac Acular®

Suitable for prescribing in primary care following specialist recommendation, in adult ocular surgery patients post-operatively.

15.01.04.02 Ketorolac Toradol®

Specialist prescribing only.

A5.08.04 K-Lite® 

Must be ordered on ONPOS, in line with OCCG Wound Management Formulary.

APCO May 2015. 

A5.08.08 Ko-Flex® 

Must be ordered on ONPO, in line with  OCCG Wound Management Formulary.

APCO May 2015. 

For more information, please see Guidance for Selecting Alternatives to Foams. 

 

A5.08.08 Ko-Flex® Long 

Must be ordered on ONPOS, in line with  OCCG Wound Management Formulary.

APCO May 2015. 

For more information, please see Guidance for Selecting Alternatives to Foams. 

A5.08.07 K-Soft® 

Must be ordered on ONPOS, in line with  OCCG Wound Management Formulary.

APCO May 2015.

A5.08.08 K-Two® 

Must be ordered on ONPOS in line with  OCCG Wound Management Formulary.

Also available as individual components - K-Tech®, K-Press®). K-Two® latex free is only for patients with latex allergy. For more information, please see Guidance for Selecting Alternatives to Foams. 

APCO May 2015. 

02.04 Labetalol 

For use in maternity for hypertension.

02.04 Labetalol 

Specialist prescribing only.

02.06.02 Lacidipine 
04.08.01 Lacosamide  Vimpat®

Suitable for continuation in primary care following specialist initiation or recommendation.

Monitoring requirements are as per the SPC. Patient would remain under specialist.

APCO January 2020.

01.06.04 Lactulose 
05.03.01 Lamivudine Epivir®

For viral hepatitis or HIV treatment. 

Funded by specialised commissioning.

APCO September 2005.

05.03.01 Lamivudine Zeffix®

For viral hepatitis or HIV treatment. 

Funded by specialised commissioning.

APCO September 2005.

04.02.03 Lamotrigine 

Suitable for continuation in primary care following specialist initiation for bipolar disorder.

Patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens.

04.08.01 Lamotrigine Lamictal®

Suitable for continuation in primary care following specialist initiation or recommendation.

16.01 Lanadelumab Takhzyro®

For preventing recurrent attacks of hereditary angioedema as per NICE TA606.

Funded by specialised commissioning.

APCO November 2019.

 

08.03.04.03 Lanreotide  Somatuline Autogel®

For the treatment of:

    • Acromegaly in line with Shared Care Protocol (APCO November 2011).
    • Neuroendocrine tumours in line with Shared Care Protocol. The OCDEM team will be responsible for prescribing the medication and delivery via the homecare team (APCO September 2016).

 

01.03.05 Lansoprazole 

Omeprazole capsules and lansoprazole capsules are the PPI preparations of choice.

For H.Pylori eradication see Guidelines for Antibiotic Prescribing in the Community 2018.

01.03.05 Lansoprazole 

For patients with swallowing difficulties.

09.05.02.02 Lanthanum Fosrenol®

Second-line to sevelamer for the control of hyperphosphataemia in patients with chronic kidney disease stage 5 who cannot tolerate calcium based phosphate binders or have pre-existing hypercalcaemia.

See Shared Care Protocol.

APCO January 2012.


11.06 Latanoprost 0.005% Eye drops 

Preserved latanoprost is available generically. Branded product £12.48 vs generic product £1.48. 

Prescribe generically. 

See Glaucoma and Ocular Hypertension Treatment Guidelines.

APCO March 2018.

11.06 Latanoprost 0.005% preservative free Monopost®

For patients intolerant or who have allergies to the preservative containing preparations only in line with Glaucoma and Ocular Hypertension Treatment Guidelines.

Suitable for prescribing in primary care following specialist recommendation.

APCO March 2018.

11.06 Latanoprost 0.005% with Timolol 0.5% PF Fixapost®

For use if prostaglandin analogue + beta-blocker indicated and preservative free product required. To be included in updated glaucoma pathway.

APCO September 2019.

05.03.03.02 Ledipasvir and Sofosbuvir Harvoni®

For treating chronic hepatitis C as per NICE TA363.

Funded by specialised commissioning.

APCO January 2016.

10.01.03 Leflunomide 

In line with Shared Care Protocol for:

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • For paediatrics use in the treatment of inflammatory disorders including Juvenile Idiopathic Arthritis, psoriatic arthritis, non-bacterial osteomyelitis and uveitis.

APCO May 2015.

08.02.04 Lenalidomide Revlimid®

Red Traffic Light

  • For treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality as per NICE TA322 (APCO November 2014).
  • Plus dexamethasone for multiple myeloma after 1 treatment with bortezomib as per NICE TA586 (APCO September 2019). 
  • Plus dexamethasone for previously untreated multiple myeloma in line with NICE TA587 (APCO September 2019). 

Funded by specialised commissioning. 

Black Traffic Light Not recommended for with bortezomib and dexamethasone for untreated multiple myeloma (NICE TA603 - terminated appraisal).

APCO November 2019.

09.01.06 Lenograstim Granocyte®

For neutropenia.

Funded by specialised commissioning.

APCO September 2007.

08.01.05 Lenvatinib Lenvima®
  • For treating differentiated thyroid cancer after radioactive iodine as per NICE TA535 (APCO September 2018).
  • for untreated advanced hepatocellular carcinoma as per NICE TA551 (APCO March 2019).

Funded by specialised commissioning. 

 

08.01.05 Lenvatinib Kisplyx®

With everolimus for previously treated advanced renal cell carcinoma in adults as per NICE TA498.

APCO March 2018.

02.06.02 Lercanidipine 
05.03.02.02 Letermovir Prevymis®

For preventing cytomegalovirus disease after a stem cell transplant as per NICE TA591.

Funded by specialised commissioning. 

 

08.03.04.01 Letrozole 

Amber Traffic Light Suitable for prescribing in primary care following Oncology Consultant recommendation for adjuvant hormonal therapy of breast cancer as per NICE TA112.

APCO May 2007.

Red Traffic Light Second line ovulation induction treatment for patients that have unsuccessful clomiphene citrate ovulation induction or are intolerable to the side effects of clomiphene citrate.

APCO September 2018.


A2.07 Leucine 100® Amino Acid Supplement

Suitable for continuation in primary care following initiation from a specialist or dietitian only.

08.03.04.02 Leuprorelin Acetate 11.25mg Prostap 3 DCS®
  • For Central Precocious Puberty (CPP) see section 06.07.02.
  • Suitable for prescribing in primary care following specialist recommendation (for indications other than CPP).
  • First-line gonadotropin-releasing hormone (GnRH) analogue for the treatment of prostate cancer is triptorelin SR 22.5mg. See GnRH analogues in prostate cancer guidelines. NB. This is a 3-monthly preparation. (APCO January 2014)
  • During COVID-19 only: For treatment of breast cancer, only for patients who cannot attend or will not attend for monthly injections during COVID-19. (APCO May 2020)

 

08.03.04.02 Leuprorelin Acetate 3.75mg Prostap SR DCS®

For Central Precocious Puberty (CPP) see section 06.07.02.

Suitable for prescribing in primary care following specialist recommendation (for indications other than CPP).

First-line gonadotropin-releasing hormone (GnRH) analogue for the treatment of prostate cancer is triptorelin SR 22.5mg. See GnRH analogues in prostate cancer guidelines. NB. This is a monthly preparation.

APCO January 2014.

04.08.01 Levetiracetam 

Suitable for continuation in primary care following specialist initiation or recommendation.

15.02 Levobupivacaine with Fentanyl 

Specialist prescribing only.

09.08.01 Levocarnitine Carnitor®

Secondary care use only to potentially reduce the usage of erythropoietin in patients on haemodialysis.

APCO January 2004.

05.01.12 Levofloxacin 

For eradication of Helicobacter pylori in line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.01.12 Levofloxacin Quinsair®

Secondary care prescribing only for adult cystic fibrosis patients. Funded by specialised commissioning.

APCO January 2019.

 

11.03.01 Levofloxacin 0.5% 

Suitable for prescribing in primary care following specialist recommendation.

13.03 Levomenthol  

Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

Brands include Arjun®, Dermacool®, Methoderm® and AquaSoothe®

Consideration should be given to the fact that all Levomenthol cream BP formulations contain aqueous cream and may cause skin irritation.

04.02.01 Levomepromazine 

Amber Traffic Light  Suitable for continuation in primary care following specialist recommendation.

Green Traffic Light  For palliative care use.

04.06 Levomepromazine Methotrimeprazine

Palliative care use only.

07.03.05 Levonogrestrel Levonelle® 1500

Levonelle® remains the first line choice of emergency contraception in patients.

Available in certain pharmacies following consultation with a pharmacist. 

07.03.02.01 Levonorgestrel 30mcg Norgeston®
06.02.01 Levothyroxine 

For treatment of primary hypothyroidism, see Management Guidelines - Thyroid Diseases.

15.02 Lidocaine 

Secondary care prescribing only.

15.02 Lidocaine 
15.02 Lidocaine 
15.02 Lidocaine 
15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
15.02 Lidocaine 5% and Phenylephrine 0.5% 

Secondary care prescribing only.

12.03.01 Lidocaine 5% ointment 

To be rubbed gently into dry gum.

Topical preparations of local anaesthetics are available to purchase in pharmacies and should only be prescribed in line with Clinical Commissioning Policy 88D.

04.07.03 Lidocaine 5% plaster Versatis®

Suitable for prescribing in primary care following specialist recommendation in line with Guidelines for the Management of Neuropathic Pain in Primary Care.

APCO March 2017.

02.03.02 Lidocaine hydrochloride 

Secondary care use only. 

15.02 Lidocaine LMX4  

Secondary care use only as pre-procedure topical anaesthesia for laser treatment.

APCO November 2018.

15.02 Lidocaine with Adrenaline Lignospan®
15.02 Lidocaine with Adrenaline Xylocaine®
15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®
06.01.02.03 Linagliptin Trajenta®

For use in patients with renal impairment. See OCCG DPP4i switch protocol

APCO November 2018. 

06.01.02.03 Linagliptin and Metformin Jentadueto®

For use in patients with renal impairment. See OCCG DPP4i switch protocol

APCO November 2018. 

05.01.07 Linezolid 

Secondary care use only. 

APCO July 2010.

06.02.01 Liothyronine 

Amber Traffic Light  Hypothyroidism for:

  • Patients currently receiving liothyronine monotherapy
  • Levothyroxine + liothyronine combination therapy for new patients with hypothyroidism
  • Patients currently receiving liothyronine and levothyroxine combination therapy

OCCG current local guidance has now been updated to be in line with the recently published RMOC guidance (June 2019). Shared care protocol is still in discussion with endocrinology.

Red Traffic Light Secondary care use only:

  • Liothyronine monotherapy: Oncology for Thyroid and parathyroid disease.

  • Liothyronine monotherapy or combination therapy for resistant depression.

APCO November 2019.

08.01.02 Liposomal cytarabine–daunorubicin Vyxeos®

For untreated acute myeloid leukaemia as per NICE TA552.

Funded by specialised commissioning.

APCO March 2019.

11.08.01 Liquid Paraffin eye ointment Xailin Night®

Treatment for dry eye syndrome, in line with Ocular lubricant prescribing guidelines. 

Also available to purchase over the counter in line with Clinical Commissioning Policy 88D

APCO July 2018.

Warning: Paraffin-based eye ointments are flammable, keep them away from heat, lights and naked flames

06.01.02.03 Liraglutide 1.2mg Victoza®

First line option in line with updated GLP-1 receptor agonist guidelines.

See patient agreement form.

APCO September 2019.

06.01.02.03 Liraglutide 1.8mg Victoza®

GP can titrate to 1.8mg if partial response. If no response consider one of the more cost effective options

See GLP-1 receptor agonist guidelines and patient agreement form.

APCO September 2019.

04.04 Lisdexamfetamine Elvanse®

For Attention Deficit Hyperactivity Disorder (ADHD) in line with Shared Care Protocol.

*Please note that adult patients will be discharged to primary care once stable as per Shared Care Protocol.

Also see:

APCO January 2018.

02.05.05.01 Lisinopril 

For heart failure, see The Management of Heart Failure in Primary Care. 

04.02.03 Lithium Carbonate Camcolit ® 400mg/ Essential Pharma 250mg

NOTE - PRIADEL TABLETS are the PREFERRED brand.

In line with Shared Care Protocol for:

    • The acute treatment of mania
    • Prophylaxis in bipolar disorder
    • To augment antidepressants in treatment refractory recurrent depression
    • The control of aggressive behaviour or intentional self-harm



APCO May 2014.

PLEASE NOTE THAT CAMCOLIT 250mg TABLETS HAVE BEEN REBRANDED TO 'Lithium carbonate Essential Pharma 250mg'. The 400mg tablets remain as 'Camcolit' brand.

04.02.03 Lithium Carbonate Priadel®

Priadel tablets are the preferred tablet brand for use in Oxford Health.

In line with Shared Care Protocol for:

    • The acute treatment of mania
    • Prophylaxis in bipolar disorder
    • To augment antidepressants in treatment refractory recurrent depression
    • The control of aggressive behaviour or intentional self-harm



APCO May 2014.

04.02.03 Lithium Carbonate Essential Pharma 250mg

In line with Shared Care Protocol for:

    • The acute treatment of mania
    • Prophylaxis in bipolar disorder
    • To augment antidepressants in treatment refractory recurrent depression
    • The control of aggressive behaviour or intentional self-harm



APCO May 2014.

04.02.03 Lithium Citrate oral solution Li-Liquid®

Li-Liquid (lithium citrate 509mg/5mL [lithium 5.4mmol/5mL) is the preferred brand of liquid lithium in Oxford Health.

In line with Shared Care Protocol for:

    • The acute treatment of mania
    • Prophylaxis in bipolar disorder
    • To augment antidepressants in treatment refractory recurrent depression
    • The control of aggressive behaviour or intentional self-harm



APCO May 2014.

NB Lithium citrate 509mg is equivalent to lithium carbonate 200mg.

14.04 Live attenuated Influenza vaccine  Fluenz Tetra®

Part of national vaccination programme.

Intranasal vaccine (Fluenz tetra®) is a live vaccine licensed for children aged 2-18ys and has different contraindications and precautions to vaccines given by injection, see SPC for more details.

APCO September 2013. 

06.01.02.03 Lixisenatide Lyxumia▼®

Restricted Item 

Existing patients only (unless high CV risk) in line with updated GLP1 guidelines.

See patient agreement form.

APCO September 2019.

A2.03.01 Locasol® 

Low calcium formula for children with conditions of calcium intolerance requiring restriction of calcium and vitamin D intake.

Suitable for continuation in primary care following initiation or recommendation from a specialist or dietitian only.

11.04.02 Lodoxamide 0.1% Eye drops Alomide®

For treating allergic conjunctivitis.

04.03.01 Lofepramine 

Lofepramine is safer in overdose and less cardiotoxic than older tricyclic antidepressants.

08.01.01 Lomustine 

Secondary care use only. 

APCO July 2008.

01.04.02 Loperamide 

Tablets are restricted for Gastroenterology and Colorectal patients requiring high doses who have swallowing difficulties (the tablets can be dispersed in water).

Oral solution (25mg/5ml) - unlicensedunlicensed - is available for short bowel syndrome where they need to give the smallest volume possible to aid absorption.

Oral solution (5mg/5ml) is available for any other patients with swallowing difficulties.

01.04.02 Loperamide  

Available to purchase over the counter. 

05.03.01 Lopinavir and Ritonavir Kaletra®

For use by Infectious Diseases and Genito-urinary Medicine only. 

Funded by specialised commissioning.

APCO September 2005.

03.04.01 Loratadine 

Available to purchase over the counter.

Only prescribe if required on a continuous basis for chronic rhinosinusitis and chronic urticaria, in line with Clinical Commissioning Policy 88D

For spontaneous urticaria in line with Management Guideline for Spontaneous Urticaria with/without Angioedema in Adults

04.01.02 Lorazepam 
04.08.02 Lorazepam 

Secondary care use only. 

15.01.04.01 Lorazepam 
02.05.05.02 Losartan 

For patients intolerant of ACE inhibitors due to cough.

03.01.05 Low range peak flow meter 
04.02.01 Loxapine  Adasuve®

For prescribing by Mental Health Specialists only.

APCO September 2017.

03.07 Lumacaftor + Ivacaftor Orkambi®

Specialist prescribing only for the treatment of cystic fibrosis in adults.

Funded by specialised commissioning.

APCO January 2020.

04.02.01 Lurasidone 

For schizophrenia.

Lurasidone is OFF-LABEL for bipolar depression. Any OH prescriber wishing to use lurasidone for this indication should complete an off-label request form and send it to the Drugs and Therapeutics Group (dtc@oxfordhealth.nhs.uk).

See Treatment of psychosis and schizophrenia algorithm

APCO March 2015.

09.01.04 Lusutrombopag Mulpleo®

For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure as per NICE TA617.

APCO March 2020.

08.03.04.03 Lutetium (177Lu) oxodotreotide Lutathera®

For treating unresectable or metastatic neuroendocrine tumours as per NICE TA539.

Funded by specialised commissioning.

APCO November 2018.

05.01.03 Lymecycline Tetralysal® 300

For:

13.06.02 Lymecycline 

Second line treatment for moderate acne vulgaris, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

APCO September 2018. 

02.05.01 Macitentan Opsumit®

For Pulmonary arterial hypertension. Only approved via Specialised centre at Royal Brompton. 

Funded by specialised commissioning - NHS E will not fund at OUH.

APCO May 2018.

01.06.04 Macrogol oral powder Movicol® Paediatric

For paediatric use only.

01.06.04 Macrogol oral powder Laxido®

For the management of acute general constipation in adults.

01.06.05 Macrogols Klean-Prep®

Secondary care use only.

01.06.05 Macrogols Moviprep®

Secondary care use only for bowel preparation for colonoscopies. Patients with stage 4 and 5 CKD (i.e.: GFR < 30ml/min) and patients unable to tolerate standard therapy (citramag® and senna) only.

09.05.01.03 Magnesium Aspartate Magnaspartate®

Treatment and prevention of magnesium deficiency, mainly for patients with short bowel syndrome after initiation by gastroenterologists.

APCO March 2015. 

09.05.01.03 Magnesium Glycerophosphate 4mmol chewable tablets 

For magnesium supplementation.

01.06.04 Magnesium Hydroxide Mixture BP 

Aqueous suspension containing about 8% hydrated magnesium oxide. Do not store in cold place.

09.05.01.03 Magnesium Sulphate injection 
13.10.04 Malathion 0.5% Derbac-M®

For the treatment of scabies if allergic to permethrin, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

02.02.05 Mannitol 

Secondary care use only. 

03.07 Mannitol dry powder for inhalation 

For treating cystic fibrosis as per NICE TA266.

Funded by specialised commissioning.

APCO January 2013.

05.03.01 Maraviroc Celsentri®

For use by Infectious Diseases and Genito-urinary Medicine only.

Funded by specialised commissioning.

APCO January 2011.

14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 
05.05.01 Mebendazole 

For treatment of threadworms, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

01.02 Mebeverine 

135mg tablet only. 

A5.03.01 Medihoney® Gel Sheet 

In line with OCCG Wound Management Formulary and Topical Antimicrobial Dressing Formulary.

For short term use. Obtain via the prescription (FP10) route.

APCO May 2015. 

06.04.01.02 Medroxyprogesterone Acetate Provera®

As adjunctive progestogen in HRT treatment, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®

Intramuscular injection.

07.03.02.02 Medroxyprogesterone acetate Sayana Press®

Subcutaneous injection.

08.03.02 Medroxyprogesterone Acetate Provera®

Suitable for continuation in primary care following specialist initiation.

10.01.01 Mefenamic Acid 

Prescribe generically. 

Tablets are more cost-effective than capsules.

05.04.01 Mefloquine Lariam®

Red Traffic Light  For malaria treatment.

Black Traffic Light  For prophylaxis of malaria.

APCO July 2010.

08.03.02 Megestrol Acetate Megace®

Suitable for continuation in primary care following specialist initiation.

04.01.01 Melatonin  Circadin®

*Circadin® brand should be used in most circumstances*

Amber Traffic Light  For sleep disorders in children and young people with complex neurological / neurodevelopmental disorders (age 1-18years) in line with Shared Care Protocol. Tablets may be crushed or halved but this will destroy the MR properties.

Also see Clinical Commissioning Policy 274

APCO September 2016.

Red Traffic Light  Specialist prescribing only for sleep EEG.

APCO January 2012.

Red Traffic Light  Specialist prescribing within Oxford Mental Health for children and adolescents.

APCO January 2012.

Black Traffic Light  For jet lag, primary insomnia, circadian rhythm sleep disorder.

APCO July 2008 and January 2012.

10.01.01 Meloxicam 

Suitable for prescribing in primary care following specialist initiation by rheumatologist.

08.01.01 Melphalan 

Secondary care use only.

APCO July 2008.

04.11 Memantine hydrochloride  

In line with Dementia Prescribing Guidelines

Amber Traffic Light For new patients not currently on AChE inhibitors – Can be prescribed in primary care following recommendation by specialist or clinician with specialist expertise, as per NICE NG97.

Brown Traffic Light For patients already on AchE inhibitors – Can be started in primary care without the need for specialist advice, as per NICE NG97.

APCO September 2018.

09.06.06 Menadiol Sodium Phosphate 

Suitable for prescribing in primary care following specialist recommendation.

Information for health care professionals on children with cystic fibrosis can be found here.

14.04 Meningococcal A, C, W135, and Y conjugate vaccine Menveo®

May not be available on the NHS if being given for travel.

14.04 Meningococcal group B Vaccine Bexsero®

Green Traffic Light  For primary immunisation schedule and asplenia/hyposplenia schedules as per Green Book.

Red Traffic Light  For patients receiving eculizumab for atypical Haemolytic Uraemic Syndrome (aHUS).

14.04 Meningococcal group C conjugate vaccine 

Brands include: Meningitec®, Menjugate Kit®, NeisVac-C®

14.04 Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax®

May not be available on the NHS if being given for travel.

06.05.01 Menotrophin 

Secondary care use only.

To induce ovulation in women who have not successfully recruited a follicle using other ovulation induction methods, and in male subfertility, to treat hypogonadotrophic hypogonadism to stimulate spermatogenesis.

APCO September 2018.

05.04.04 Mepacrine Hydrochloride 

Secondary care use only for giardia unresponsive to first and second line treatment.

APCO May 2017. 

A5.04.02 Mepiform® 

Please liaise with specialist service e.g. plastics TV for support. 

MUST be authorised by TV team before ordering (oxfordhealth.tissueviability@nhs.net or tissueviability@oxfordhealth.nhs.uk).

Please see OCCG Wound Management Formulary

APCO May 2015.

A5.02.03 Mepilex lite 

Secondary care use only. 

APCO July 2006.

A5.02.03 Mepitel 

Secondary care use only. 

APCO July 2006.

15.02 Mepivacaine Scandonest Plain®

Specialist prescribing only.

03.04.02 Mepolizumab Nucala®

For treating severe refractory eosinophilic asthma as per NICE TA431.

Funded by specialised commissioning.

APCO March 2017.

01.05.03 Mercaptopurine 

For the treatment of inflammatory bowel disease in line with Shared Care Protocol.

APCO November 2015.

08.01.03 Mercaptopurine 

For the treatment of acute leukaemias, chronic myeloid leukaemia, cancer.

05.01.02.02 Meropenem Meronem®

Secondary care use only. 

APCO July 2010.

05.01.02.02 Meropenem with Vaborbactam Vaborem®

Specialist prescribing only. 

APCO March 2020.

01.05.01 Mesalazine Octasa®

Suitable for prescribing in primary care following specialist recommendation.

Prescribe by brand.

01.05.01 Mesalazine Asacol®

For existing patients only - Octasa® brand is preferred for new patients as it is similar and more cost effective. 

01.05.01 Mesalazine Pentasa®

Suitable for prescribing in primary care following specialist recommendation.

Prescribe by brand.

01.05.01 Mesalazine Salofalk®

Suitable for prescribing in primary care following specialist recommendation.

Prescribe by brand.

08.01 Mesna 

Secondary care use only. 

APCO July 2008.

06.04.02 Mesterolone Pro-Viron®

Suitable for continuation in primary care following specialist initiation.

07.03.01 Mestranol 50mcg / norethisterone 1mg Norinyl-1®

Monophasic standard strength (21 day preparation).

02.07.02 Metaraminol 

Specialist prescribing only.

06.01.02.02 Metformin Hydrochloride 

APCO September 2016.

06.01.02.02 Metformin Hydrochloride 

For primary care only if GI intolerance to standard release formulation.

APCO September 2016.

06.01.02.02 Metformin Hydrochloride 

Only for patients with swallowing difficulties.

Drug tariff special.

APCO September 2016.

04.07.02 Methadone 

Suitable for continuation in primary care following specialist initiation.

04.10.03 Methadone 1mg/ml oral solution  

For substance misuse refer patients to Oxfordshire Drug and Alcohol recovery service (Turning Point).

Referrals to Turning Point can be made via a dedicated form on GP Proforma Practice systems.

They also accept self-referrals from professionals, organisations, individuals and concerned family members or friends, using the referral form available on their website.

Contact details:


APCO July 2011.

05.01.13 Methenamine Hippurate Hiprex®

For long-term low dose prophylaxis in non-pregnant women with recurrent UTI, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Long-term low dose prophylaxis for 3-6 months then review recurrence rate and need. Consider adding in Ascorbic Acid to possibly enhance acidity of urine.

APCO September 2018.

08.01.03 Methotrexate 10mg tablets 

Secondary care use only. 

APCO March 2004.

01.05.03 Methotrexate 2.5mg tablets 

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

10.01.03 Methotrexate 2.5mg tablets 

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

11.99.99.99 Methotrexate 2.5mg tablets 

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

13.05.03 Methotrexate 2.5mg tablets 

Only 2.5mg tablets should be prescribed and dispensed to avoid potentially fatal errors.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

01.05.03 Methotrexate injection Metoject®

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

10.01.03 Methotrexate injection Nordimet®

*Metoject® injection is the first choice in Oxfordshire*

Second line to metoject. For use in patients who are unable to use/ have compliance issues with metoject device.

APCO September 2019.

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

10.01.03 Methotrexate injection Metoject®

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

 

11.99.99.99 Methotrexate injection Metoject®

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

13.05.03 Methotrexate injection Metoject®

*Metoject® injection is the first choice brand of injection which should be used in Oxfordshire*

For use in adults and paediatrics line with Shared Care Protocol for:

  • Dermatology
  • Neurology
  • Gastroenterology
  • Respiratory

Rheumatology

For rheumatology please prescribe in line with Shared Care Protocol here. 

APCO September 2019

Opthalmology

For opthalmology (ocular inflammation) please prescribe in line with Shared Care Protocol here. 

APCO May 2019.

09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

Secondary care use only. 

Funded by specialised commissioning.

APCO November 2005.

13.05.02 Methoxypsoralen 

For prescribing by dermatologists only in secondary care. For photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) treatment only. 

8-methoxypsoralen 10mg tablets (Puvasoralen®)
5-methoxypsoralen 20mg tablets (Pentaderm®)

CAUTION:  Methoxypsoralen is administered prior to Psoralen and UVA treatment (PUVA).  There are two different oral compounds available, 5-methoxypsoralen and 8-methoxypsoralen.  The UVA light dose administered depends on the photosensitising agent taken before treatment and the dose of the two compounds differs.  5-methoxypsoralen and 8-methoxypsoralen are different compounds and are not interchangeable.

13.08.01 Methyl-5-Aminolevulinate Metvix®

For prescribing by dermatologists only in secondary care. For photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) treatment only. 

02.05.02 Methyldopa 
04.04 Methylphenidate Hydrochloride 

For Attention Deficit Hyperactivity Disorder (ADHD) in line with Shared Care Protocol.

*Please note that adult patients will be discharged to primary care once stable as per Shared Care Protocol.

Also see:

APCO January 2018.

04.04 Methylphenidate Hydrochloride MR 

NB. Branded generics of choice include Delmosart and Xaggitin XL.

For Attention Deficit Hyperactivity Disorder (ADHD) in line with Shared Care Protocol.

*Please note that adult patients will be discharged to primary care once stable as per Shared Care Protocol.

Also see:

APCO January 2018.

06.03.02 Methylprednisolone 

Suitable for continuation in primary care following specialist initiation.

10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine
04.06 Metoclopramide 

Green Traffic Light  For palliative care.

Restricted Item  Brown Traffic Light  For all other indications. Short term use (up to 5 days) in line with MHRA advice. Not recommended for patients under 20 years of age due to risk of dystonic reactions.  

 

02.02.01 Metolazone 

For use in secondary care by Cardiology for diuretic resistance and heart failure only.

04.07.04.02 Metoprolol 

For prohylaxis of migraine in line with Migraine: Adult Prophylactic Therapy Guidelines

APCO January 2016. 

02.04 Metoprolol Tartrate 

Second line to bisoprolol for secondary prevention of coronary atery disease (e.g. post STEMI/NSTEMI).

02.04 Metoprolol Tartrate 

Specialist prescribing only.

05.01.11 Metronidazole 

Secondary care use only. 

APCO July 2010.

05.01.11 Metronidazole 

In line with Guidelines for Antibiotic Prescribing in the Community 2018.

05.04.03 Metronidazole 

Treatment of choice for Trichomonas vaginalis infection, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

07.02.02 Metronidazole 0.75% Zidoval®

For the treatment of bacterial vaginosis, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Metronidazole is reserved to patients allergic to clindamycin. 

13.10.01.02 Metronidazole topical 0.75%  

First line treatment of mild & localised papulopustular rosacea, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Acea®, Anabact®, Rozex® brands are more cost-effective. 

Other more expensive brands include (non-formulary): Zyomet® gel, Metrosa® gel, Rosiced® cream, Metrogel®, Metrotop®, Noritate®.

06.07.03 Metyrapone Metopirone®

Specialist prescribing only.

02.03.02 Mexiletine 

Secondary care use only.

For refractory ventricular tachycardia - restricted to EP electro physiological consultants only; and for the treatment of myotonia in patients under the care of Dr. Hilton-Jones.

05.02.04 Micafungin Mycamine®

Secondary care use only. 

07.02.02 Miconazole Gyno-Daktarin®

One of first line options for treatment of vaginal candidiasis in non-pregnant women.

First line treatment of vaginal candidiasis in pregnant women, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

12.03.02 Miconazole Daktarin®

First-line treatment for oral candidiasis for immunocompetent adult and children older than 2 years of age, in line with Guidelines for Antibiotic Prescribing in the Community 2018.

Available to purchase over the counter in line with Clinical Commissioning Policy 88D.

13.10.02 Miconazole 2% 

For cutaneous candidiasis - apply until 10 days after lesions healed. Can be purchased over the counter, in line with Clinical Commissioning Policy 88D.

See Guidelines for Antibiotic Prescribing in the Community 2018.

06.01.01.03 Microdot Droplet 

BD Viva and GlucoRx FinePoint are first-line choices for insulin pen needles.

APCO November 2016.

01.06.04 Micro-enema 
06.04.01.02 Micronised Progesterone Utrogestan®

As adjunctive progestogen in HRT treatment, in line with Oxfordshire HRT formulary and treatment guidance. 

APCO January 2016. 

15.01.04.01 Midazolam pre-med

For oral sedation in children undergoing stressful procedures or as a pre-med. 

04.08.02 Midazolam Buccal Epistatus®

Prescribe by brand.

For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus in line with Shared Care Protocol.

APCO September 2011.

04.08.02 Midazolam Buccal Buccolam®

Prescribe by brand.

For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus in line with Shared Care Protocol.

APCO September 2011.

15.01.04.01 Midazolam injection 

Green Traffic Light  For palliative care - 10mg/2ml strength.

Red Traffic Light  For all other indications.

15.01.04.01 Midazolam intranasal  

For use by the Oxfordshire Salaried Primary Care Dental Service only for special care adults and adults with needle phobia subject to the medico-legal aspects being agreed with Oxford Health.

APCO March 2011.

02.07.02 Midodrine Bramox®

Suitable for continuation in primary care following specialist initiation, in line with local amber continuation guideline.

Licensed product is now available. Limited evidence of effectiveness of midodrine and need for ongoing monitoring by the GP.

APCO July 2017.

08.01.05 Midostaurin Rydapt®

Red Traffic Light  For untreated acute myeloid leukaemia as per NICE TA523.

Funded by specialised commissioning.

APCO July 2018.

07.01.02 Mifepristone Mifegyne®

Secondary care use only. 

09.08.01 Migalastat Galafold®

For treating Fabry disease as per NICE HST4. To be prescribed by specialist centres only.

APCO March 2017.

Funded by specialised commissioning.

02.01.02 Milrinone Primacor®

Secondary care use only. 

05.01.03 Minocycline 

Not recommended for acne, in line with NHS England Items which should not routinely be prescribed in primary care guidance.

APCO September 2019.

02.05.01 Minoxidil Loniten®

Amber Traffic Light  For continuation in primary care following specialist initiation for hypertension.

Black Traffic Light  For androgenic alopecia. Oral tablets are not licensed for this indication and the solution Regaine® is not available on the NHS (APCO July 2018). 

07.04.02 Mirabegron Betmiga®

In line with The Management of Over Active Bladder Syndrome Guidelines.

  • Second-line option if antimuscarinic drugs are contra-indicated
  • Third-line option if antimuscarinic drugs have not been effective and mirabegron is not contra-indicated


NB. Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both). Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension. MHRA Oct 2015.

APCO March 2017.

04.03.04 Mirtazapine 

First choice antidepressant if sedation is required, or if SSRI related adverse effects are unacceptable (GI bleeding, hyponatraemia, sexual dysfunction, insomnia).

See